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 Abbreviations 
 
Ang1 Angiopoietin 1 
ANOVA Analysis of variance 
bp Base pairs 
BSA Bovine serum albumin 
cDNA Complementary deoxyribonucleic acid. 
DMEM Dulbecco’s modified Eagle Medium. 
DMSO Dimethyl sulfoxide 
dNTP Deoxyribonucleotide triphosphate 
EDTA Ethylenediaminetetra-acetic acid 
eg. Exemple 
ELISA  Enzyme-linked immunosorbent assay  
F-ALK Alkaline extract of adult S. venezuelensis 
F-ES Female excretory/secretory antigens of S. venezuelensis 
FGF-2 Fibroblast growth factor-2 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HIF-1 Hypoxia-inducible factor 1 
HSPG Heparin sulfate proteoglycans 
iNOS Inducible nitric oxide synthase 
i.p Intraperitoneal  
Ig Immunoglobulin  
IL Interleukin  
L3 Larval stage of nematodes  
L3-ES Excretory/secretory antigens of larvae the S. venezuelensis 
L3-PBS PBS-soluble extract antigen of larvae the S. venezuelensis 
L-NAME Nw-Nitro-L-arginine methyl ester 
LPS Lipopolysaccharide 
lsrRNA Large subunit RNA 
mRNA Messenger RNA 
mtRNA Mitochondrial RNA 
MTT 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NO Nitric Oxide 
nRNA Nuclear RNA 
OD Optical density  
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PDGF Platelet-derived growth factor 
p.i. Post-infection  
PlGF Placental growth factor 
PMSF Phenilmethysulfonylfonylfluoride 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline  
PCR Polymerase chain reaction  
RNA Ribonucleic acid  
rRNA Ribosomal RNA 
RT-PCR Reverse transcriptase polymerase chain reaction 
Σ Sum (statistic)  
s.c. Subcutaneous  
SD Standard deviation 
SEM Standard error of the mean  
sp/spp Specie/species  
ssrRNA Small subunit RNA 
TNF Tumour necrosis factor  
tRNA Transfer RNA 
uv Ultraviolet  
VEGF Vascular Endothelial Growth Factor 
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Knowledge on angiogenesis control has been a major advance in the understanding 
of the pathogenesis of many diseases in the last decades. The studies about the role of 
angiogenic and antiangiogenic factors in the biology of neoplastic (tumor growth and 
development of metastases) are most abundant in the literature. However, both the 
generation and inhibition of new vessel formation plays an important role in other 
pathophysiological processes (eg. ischemia, infection and inflammation). 
Firstly, we have divided the introduction in three sections: we briefly point out the 
basic concepts of angiogenesis and vasculogenesis, as well as their role in neoplastic 
and non-neoplastic diseases. 
In a second section we study the characteristics of the two major angiogenic factors: 
vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2). 
Specifically, the structural features of the above factors and the biological mechanism of 
action will be indicated. Also, antiangiogenic factors as endostatin, a potent inhibitor of 
endothelial cell proliferation, migration, angiogenesis and tumor growth will be studied.  
Finally, we discuss the role of angiogenic and antiangiogenic factors in the 
pathogenesis of helminthic diseases. Until now, only very little information has been 
found and virtually confined to infection with Schistosoma spp, filarial species, Taenia 
solium and Trichinella spp. 
1.1 Angiogenesis 
Vertebrates, including mammalian species, have a closed circulation system for 
supplying nutrient and oxygen to the tissues in the body. The large and small blood 
vessels in this circulation system consist of two major cell types, one is the vascular 
endothelial cells lining the inside of the vessels (monolayer), and the other is the smooth 
muscle cells which regulate the contraction and dilation of blood vessels. The blood 
vessels are developed by several steps in embryogenesis, vasculogenesis (blood vessel 
formation from precursor cells), angiogenesis (blood vessel formation from pre-existing 
vessels and vascular endothelial cells), and vascular remodelling. 
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Angiogenesis, the process of new blood vessel formation from pre-existing ones, 
plays an important role in various physiological and pathological conditions, including 
embryonic development, wound repair, inflammation, and tumor growth (Carmeliet and 
Jain, 2000). Uncontrolled release of angiogenic growth factors and alteration of the 
production of natural angiogenic inhibitors, with a consequent modification of the 
angiogenic balance, are responsible for the uncontrolled endothelial cell proliferation 
that takes place during tumor neovascularization and in angiogenesis dependent diseases 
(Folkman, 2000). 
Animal cells need oxygen and nutrients for their life and are there located within 
100-200 µm of blood vessels with a limit for oxygen (Figure 1.1). For each organism 
that growth beyond this size, they must recruit new blood vessels by vasculogenesis and 
angiogenesis. Undoubtly blood vessels are essential for growing tumors; metastasize to 
another organ and also for treatment and deliver drugs to all regions of a tumor in 
effective quantities (Carmeliet, 2000).  
 
                 Figure 1.1: Oxygen gradient concentration in tissues 
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1.1.1 Angiogenesis in tumors 
In 1971, Folkmann proposed that tumor growth and metastases depend on 
angiogenesis, and therefore blocking angiogenesis could be a strategy to stop tumor 
growth. 
In the initial stages of malignant tumors there is a balance between the proliferation 
of neoplastic cells and their destruction, by both apoptosis and immune control. When 
the primary tumor reaches a size limit, the local concentration of oxygen decrease and 
then cells produce angiogenic factors. Moreover, tissue destruction leads to the next 
release of antiangiogenic substances. Given that the average life of anti-angiogenic 
factors is greater than the stimulant, initially tumor growth and metastasis development 
is controlled. However, when the balance is altered in favor of proangiogenic activity, 
takes place the formation of new vessels with the consequences noted in following 
sections. 
Pro-angiogenic factors includes several molecules released by parenchymal or 
inflammatory cells in response to mechanical factors, metabolic (eg. hypoxia, acidosis) 
or immune response. Moreover, tissue destruction leads to generation of molecules with 
antiangiogenic potential. Table 1.1a and 1.1b include the main substances identified, 
based on the literature (O'Reilly et al. 1997, Sathornsumetee and Rich, 2007). The 
predominance of angiogenic factors leads to the formation of new blood vessels from 
endothelial precursors both local and mobilized from the bone marrow. 
Tumor angiogenesis involves both blood vessels and the lymphatics vessels. 
Regarding to blood vessels can be observed differences in comparison with the normal 
vasculature. Thus, from a macroscopic point of view, the distribution is very 
disorganized with dilated tortuous vessels, an irregular diameter and excessive 
branching and shunts. Microscopically, the endothelium has numerous openings 
(fenestrate endothelial, vesicles, transcellular holes), are widened intercellular junctions 
and basement membrane is discontinuous or absent. The smooth muscle surrounding 
the endothelial cells does not contract in response to normal stimuli, which limits the 
use of vasoconstrictors in antitumor treatment. The main alterations of lymphatics 
vessels were compression of the localized within the tumor and dilation of those located 
in the periphery (by excess VEGF-C, see below). These enlarged lymph vessels can 
pick neoplastic cells derived from the surface of the tumor and thereby facilitate 
lymphatic metastasis. 
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Table 1.1a: Pro-angiogenic factor receptors their abbreviations and 
functions. 
Factor/Receptor Abbreviations Functions 
Vascular endotelial growth 
factors 
VEGFs Stimulates vasculogenesis 
Stimulates angiogenesis 
Increases vascular permeability 
Promotes leucocyte adhesion 
Vascular endotelial growth 
factor receptors 
VEGFRs Integrate angiogenic and survival 
signal  
Neuropilin-1 NRP-1 
Angiopoietin-1 Ang-1 Stabilize vessels  
Inhibit permeability  
Angiopoietins receptor Tie-2 
Platelet derived growth factor- 
BB 
PDGF-BB  Recruit smooth muscle cells 
Transforming growth factor β1 TGF-β1  Stimulate extracellular matrix 
production  
Endoglin  
Fibroblast growth factor-2 FGF-2  Stimulates angiogenesis 
Integrins αvβ3, αvβ5, α5β1   Receptors for matrix 
macromolecules and proteinases  
VE-Cadherine CD31 Endothelial junctional molecule  
Ephrins   Regulate arterial/venous 
determination  
Matrix metalloproteinases  MMPs  Remodel matrix, release and 
activate growth factors  
Nitric oxide synthases NOSs Vasodilate 
Stimulate angiogenesis Cyclooxygenase-2 COX-2 
Antigen 133 CD133 Angioblast (circulant endothelial 
precursor) differentiation 
Inhibitors of differentiation 1/3 Id1/Id3  Determine endothelial plasticity  
 
Introduction  -17- 
Table 1.1b: Anti-angiogenic factor receptors their abbreviations and 
functions. 




Soluble VEGFR-1 Sink for VEGF, VEGF-B 
Angiopoietin 2 Ang-2 Natural antagonist of angiopoietin 1 
Thrombospondin 1/2 TSP-1 /TSP2 Inhibits endothelial migration, growth, 
adhesion and survival 
Angiostatin  Suppress tumor angiogenesis  
Endostatin (collagen 
XVIII fragment) 




 Inhibits endothelial proliferation 
Platelet factor 4 PF-4 Inhibits binding of VEGF and FGF-2 
Tissue inhibitors of 
metalloproteinases 
TIMPs 
Suppress pathological angiogenesis 
Proteolytic fragment of 
metalloproteinase II 
PEX 
 Meth-1 /Meth-2 Angiogenesis inhibitors that contain 
metalloprotease, thrombospondin and 
disintegrin domains 
Cytocines IFN-α, -β,-γ; IP-10, 
IL-4, IL-12, IL-18  
Inhibits endothelial migration; 
Downregulate FGF-2 
Prothrombin  Suppress endothelial growth  
Prolactin  Inhibits VEGF and FGF-2 
Vascular endothelial 
growth factor inhibitor 
VEGFI Inhibitor of endothelial growth and 
angiogenesis 
Secreted protein, 
acidic, cysteine-rich  
SPARC Inhibit endothelial binding and 
activity of VEGF  
Osteopontin  Interference with interin signaling 
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The vascular changes described in the previous section determine chaotic 
intratumoral blood flow with appearance of areas of hypoxia and acidosis, which can 
select cells that have lost their apoptotic response to hypoxia, which is then clonally, 
expand. Furthermore, the identified angiogenic factors can modulate the expression of 
cell adhesion molecules and other surface markers on tumor vascular endothelium. For 
example, VEGF and tumor necrosis factor-α (TNF-α) upregulate, while the growth 
fibroblast growth factor (FGF) and transforming growth factor-β1 (TGF-β1) 
downregulate adhesion molecules. Both phenomena (chaotic blood supply and non-
uniform expression of adhesion molecules) explain the low and irregular interaction 
between leukocytes and endothelium in tumor vessels. 
Finally, we note that the above phenomena depend on both the tumor type and the 
location in relation to the type of stromal cells present (Gohongi et al., 1999)  
1.1.2 Angiogenesis in non-neoplastic diseases 
Inflammation and hypoxia contribute to angiogenesis in non-neoplastic diseases. In a 
healthy adult, endothelial cells of blood vessels are in a quiescent state. In the presence 
of hypoxia or inflammation vascular remodeling occurs with formation of new vessels. 
One aspect of particular interest is that angiogenesis in non-neoplastic, unlike the 
neoplastic vessels, lead to the formation of blood vessels with a normal structure and 
function. 
Hypoxia is therefore a very important stimulus of angiogenesis as other biological 
processes that attempt to restore normal tissue oxygenation (Figure 1.2). The basic 
mechanism is the activation of a protein called HIF-1 (hypoxia-inducible factor 1). HIF-
1 is a heterodimeric protein formed by the junction of two subunits (HIF-1α and HIF-
1β). While HIF-1β is constitutively expressed in all tissues, HIF-1α is activated in 
hypoxic conditions. HIF-1 acts on the promoter region of different genes that have a 
common response element (HRE, HIF-1 responsive element). The main genes activated 
by HIF-1 are: 
- Genes encoding glucose transporters (GLUT-1) or enzymes of glycolysis. The 
result is a stimulation of anaerobic glycolysis and therefore an increase in lactate 
production. 
- Erythropoietin gene in kidney. Increased release of erythropoietin stimulates the 
proliferation and differentiation of erythropoietic precursors. 
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- Gen of tyrosine hydroxylase, key enzyme in the synthesis of dopamine in the 
carotid bodies responsible for the circulatory and ventilatory response to hypoxia 
- Genes related to angiogenesis such as VEGF, inducible nitric oxide synthase 







                     Figure 1.2. Integrative response to hypoxia. 
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Furthermore, during inflammation, there is recruitment and activation of blood cells 
to the focal lesion. Many of these cells (eg. macrophages, platelets, eosinophils, mast 
cells and other leukocytes) release pro-angiogenic factors summarized in Table Ia. In 
addition, professional phagocytes are capable of releasing proteases releasing 
angiogenic factors of the extracellular matrix.  
As the previous data, angiogenesis changes such as excess or deficiency have been 
observed in multiple diseases where hypoxia or inflammation plays an important role. 
In particular there have been changes in angiogenesis in various types of systemic 
diseases, both autoimmune diseases (eg. rheumatoid arthritis, lupus erythematosus, 
systhemic sclerosis) (Carvalho et al., 2007), metabolical diseases (diabetes mellitus) 
(Crawford et al., 2009) or hematological diseases (Castleman´s disease) (Nishi et al., 
2000). Moreover, modifications in angiogenesis have seen detected in localized 
diseases: gastrointestinal tract (eg. Crohn's disease) (Carvalho et al., 2007), eyes (age-
related macular degeneration) (Bressler, 2009), central nervous system (ie. multiple 
sclerosis, Alzheimer's disease) (Carvalho et al., 2007, Carmeliet et al., 2002) and 
respiratory diseases (pulmonary emphysema, idiopathic pulmonary fibrosis) (Richter et 
al., 2005) or kidney diseases (glomerulonephritis) (Foster, 2009). 
1.2 Angiogenic and anti-angiogenic factors. 
1.2.1 Vascular Endothelial Growth Factor (VEGF). 
The vascular endothelial growth factors (VEGFs) are pleiotropic polypeptides 
produced by different cell types, including eosinophil (Horiuchi and Weller, 1997). 
From the early of 1980s that VEGF was identified independently as vascular 
permeability factor (VPF) and as vascular endothelial cell-specific growth factor in 
1980s (Senger et al., 1983; Leung et al., 1989), more studies have been carried out 
about structure and function of these molecules. In this section, we review briefly the 
most important aspects of these molecules.  
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1.2.1.1 Structure of VEGFs 
The VEGFs belong to the VEGF-PDGF (platelet-derived growth factor) super-gene 
family characterized by 8 cysteine residues are at the same position. 2 out of 8 cysteins 
generate intermolecular cross-linking, and other 6 cysteins make 3 intramolecular bands 
to form 3 loop structures (Figure 1.3) (Shibuya, 2001). 
 
                                Figure 1.3: Monomer of VEGF-F 
 
Seven molecules of VEGF family have been identified (VEGF-A, VEGF-B, VEGF-
C, VEGF-D, placental growth factor (PlGF), VEGF-E and VEGF-F). In the mammals, 
only the first five have biological importance, VEGF-E is a viral protein [Orf-virus 
(open reading frame, in the genome of Orf virus)-derived VEGF] (Shibuya, 2003) and 
VEGF-F a protein derived from snake venom (Tokunaga et al., 2005). 
Among angiogenic factors identified in humans, vascular endothelial growth factor-
A (VEGF-A) appears to mediate the basic signalling of angiogenesis (often referred to 
as simply VEGF). Table 1.2 has shown genetic and functional differences of the five 
VEGF synthesized in mammals.  
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Table 1.2: Types of VEGFs. 
 
VEGF-A exists as multiple isoforms resulting from alternative pre-mRNA splicing 
of eight exons (Ladomer et al., 2006). The isoforms are named according to the amino 
acid number of the monomer, generically termed VEGFxxx. The general nomenclature of 
these proteins include, in addition to the general designation (VEGF) ,the total number 
of amino acids (xxx) and a suffix (b), if the alternative processing affects the distal 
portion of exon 8. The total number of amino acids derived mainly from the inclusion or 
not of amino acids encoded (totally or partially) by exons 6 and 7 (Figure 1.4). 
These structural features have a clear biological significance. Thus, the inclusion or 
exclusion of exons 6 and 7 modulates interactions with heparan sulfate proteoglycans 
(HSPGs) and neuropilin receptors. Furthermore, proximal or distal processing of exon 8 
has functional consequences, as VEGFxxx isoforms are proangiogenic and VEGFxxxb are 
antiangiogenic. 
The major human isoforms of VEGF-A are VEGF206, VEGF189, VEGF189b, VEGF165, 
VEGF165b, VEGF121 and VEGF121b. In proangiogenic forms, the isoform that has a 
major biological importance is VEGF165, followed by VEGF121, VEGF189 and VEGF206. 
 
 
 VEGF-A VEGF-B VEGF-C VEGF-D PlGF 
Chromosome 6p23.1 11q.13 4q34 Xp22.31 14q.24 



















   Figure 1.4. Isoforms of VEGF-A. 
1.2.1.2 Biological effects of VEGF 
VEGF-A exerts its biologic effect through interaction with cell-surface receptors. 
The receptors for VEGFs are 5 main types (Otrock et al., 2007): VEGF receptor-1 
(VEGFR-1; Flt-1), VEGF receptor-2 (VEGFR-2; Kinase insert domain-containing 
receptor/Flk-1), VEGF receptor-3 (VEGFR-3; Flt-4), selectively expressed on vascular 
endothelial cells, and neuropilin receptors (NP-1 and NP-2), expressed on vascular 
endothelium and neurons (Figure 1.5). VEGF-A is capable of binding to all of them 
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                           Figure 1.5. VEGFs receptors. 
VEGFR-1, also called fms-like tyrosine kinase, Flt-, is a molecule constituted by 7 
extracellular Ig-type domains, a transmembrane region and an intracellular tyrosine 
kinase domain. This molecule is expressed on endothelial cells, osteoblasts, 
mononuclear phagocytic system cells, placental trophoblast cells, mesangial cells and 
some hematopoietic stem cells (Zachary and Gliki, 2001). Although the affinity of 
VEGFR-1 by VEGF-A is 100 times greater than the rates for VEGFR-2, the tyrosine 
kinase activity of VEGFR-1 is lower. In embryogenesis, the expression of VEGFR-1 is 
linked to a negative effect on angiogenesis (Shibuya, 2001). In subsequent periods, the 
binding VEGF-A to VEGFR-1 appears to play an important role in the generation of 
paracrine signaling in endothelial cells. 
VEGFR-2 (also called KDR: kinase-insert domain receptor or flk-1: fms-like kinase) 
has a structure very similar to VEGFR-1. This receptor is mainly expressed in 
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endothelial cells, but it has also been demonstrated in neurons, megakaryocytes, 
osteoblasts and hematopoietic cells. The main action of VEGF-A is exerted by 
interaction with this receptor. 
The neuropilin 1 and 2 were identified as recipients of a family of molecules known 
as semaphorins/collapsin, a family of molecules regulating the development of the 
nervous system. Both are expressed during embryonic development in nervous tissue, 
cardiovascular, skeletal, while in adults its expression is very wide (Bielenberg, et al., 
2006). The role of neuropilin, mainly of NP-1 is to act as a co-receptor for VEGFR-2 by 
increasing its biological action. 
Multiple cell types are capable of trigger synthesis and release of VEGF-A in 
response to very different stimuli such as metabolic changes (hypoxia, hypoglycemia), 
hormonal (estrogens), cytokines and other growth factors, proinflammatory molecules 
and genetic disorders (Shibuya, 2003, Neufeld et al., 1999). One of the best 
characterized is hypoxia, which induces the stabilization and translocation to the 
nucleus of two HIF subunits. The union of HIF-1α and HIFβ interacting with a specific 
region of the VEGF gene (HRE, hypoxia response element) induces the synthesis of this 
molecule (Liao and Johanson, 2007). On the other hand, hypoglycemia, both in 
laboratory studies (Neufeld et al., 1999) and clinical settings (Dantz et al., 2002) leads 
to an increased synthesis of VEGF. Estrogens also play an important role in inducing 
VEGF production in both physiological situations (menstrual cycle, ovulation) and 
pathological (breast cancer) (Hyder and Stancel, 1999). Multiple cytokines and growth 
factors (Table 1.3) induce the production of VEGF (Neufeld et al., 1999). 
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Table 1.3. Cytokines that stimulates the production of VEGF. 
Cytokine Abbreviations 
Fibroblast growth factor 4 FGF-4 
Granulocyte-macrophage colony stimulating factor GM-CSF 
Insulin-like growth factor-1 IGF-I 
Interleukin 1 IL-1 
Interleukin 5 IL-5 
Keratinocyte growth factor KGF 
Transforming growth factor ß TGF-ß 
 
Among the inflammatory mediators associated with the production of VEGF are 
oxygen free radicals (Brauchle et al., 1996) and nitric oxide (Chin et al., 1997). Finally, 
several kinds of genetic alterations present in tumour hereditary diseases or associated 
with overproduction of VEGF. The best characterized are associated with p53 
mutations, the gene encoding the protein of von Hippel-Lindau and PTEN (phosphatase 
and tension homologue deleted on chromosome 10). 
The interaction of VEGF-A and VEGFR-2 receptor triggers a series of initial 
signaling mechanisms that can be summarized into 5 phases (Schlessinger, 2000): (i) 
ligand binding to the receptor, (ii) receptor of dimerization; (iii) activation of tyrosine 
kinases, (iv) receptor of autophosphorylation and (v) binding and activation of adapters 
to autophosphorylation sites. The signalling pathway of VEGF/VEGFR-2 is different 
from other growth factors and is summarized in Figure 1.6. 
Basically after the interaction between VEGF-A and VRGFR-2, four transduction 
pathways are activated: (i) Activation of PI3K (represented in purple/violet colours) that 
converts PIP2 into PIP3. This molecule acts in two ways on the effects of VEGF, first 
by inhibition of apoptosis (on BAD and caspase 9) and second by stimulating the nitric 
oxide production by endothelial isoenzyme action on the ONS. (ii) CDC42 activation 
displayed in share of green which eventually leads to a reorganization of the actin 
filaments, (iii) Diminished adhesion of endothelial cells (indicated in brown/orange) 
using as adapter molecule Src and (iv) activation of phospholipase C gamma (via 
represented in blue) starting from PIP2 generates DAG and IP3. The consequences of 
this approach are twofold: the generation of prostaglandins and activation of endothelial 
cell proliferation. 
Introduction  -27- 
In summary, the four mechanisms by which VEGF leads to angiogenesis are: (i) 
increased cell survival, (ii) increase cell migration, (iii) stimulate of cell proliferation 
and (iv) increase of permeability. 
 
                     Figure 1.6. Signalling through VEGFR-2. 
1.2.2 Fibroblast Growth Factor-2 (FGF-2) 
FGF-2 or basic FGF (fibroblast growth factor) represents the best-characterized 
member of the larger family of heparin-binding growth factors.  FGF-2 is a potent 
angiogenic molecule in vivo and in vitro stimulates smooth muscle cell growth, wound 
healing and tissue repair (Nugent and Iozzo, 2000). In addition, FGF-2 may stimulate 
hematopoiesis and may play an important role in the differentiation and/or function of 
the nervous system, the eye and the skeleton.  
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1.2.2.1 Structure of FGF-2  
FGF-2 was firstly identified as a 146-amino acid that was later found a represent to 
proteolytic product of the primary 18 kDa heparin binding protein. Larger forms of 
FGF-2 have been identified with 22, 22.5, 24 and 34 kDa, resulting from alternate 
CUG-translation start sited. FGF-2 contains four cystein residues with no intramolecular 
disulfide bands, a large number of basic residues with an isoelectric point of 9.6 and two 
sites that can be phosphorylated by protein kinases A and C, respectively (Bikfalvi et 
al., 1997). 
The interaction of FGF-2 with heparin protects this growth factor against heat or acid 
denaturation and protease cleavage. While heparin is only synthesized by connective 
tissue mast cells, heparin sulfate is widely distributed throughout all mammalian tissue 
and organs attached to core proteins as heparin sulfate proteoglycans (HSPG). HSPGs 
are a functionally diverse class of molecules found on cell surfaces and in the 
extracellular matrix where they have been shown to interact with FGF-2 and modulate 
its distribution and function. The specific sites on FGF-2 involved in binding to heparin 




                        Figure 1.7: X-ray crystal structure of FGF-2 
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1.2.2.2 Biological effects of FGF-2 
FGF-2 plays key roles in development, remodelling and disease states in almost 
every organ system (Table 1.4). 
Table1.4: Functions of FGF-2. 
Organ Putative functions 
Blood vessel Angiogenesis 
Smooth muscle cell proliferation 
Blood pressure control 
Atherogenesis 
Central nervous system Neuronal differentiation and survival 
Lung Branching morphogenesis 
Fibrosis 
Limb Limb development 
Muscle Myogenesis 
Bone Stimulation of osteoblasts 
Reproductive system Spermatogenesis 
Eye Photoreceptor survival and transduction 
Stimulation of lens epithelial cells 
Proliferation of corneal  
Skin Melanogenesis 
Morphogenesis of the suprabasal keratinocytes 
 
One of the best characterized activities of FGF-2 is its ability to regulate the growth 
and function of vascular cells such as endothelial and smooth muscle cells. FGF-2 has 
been implicated in the development and growth of new blood vessels (angiogenesis) 
and in the pathogenesis of vascular disease such as atherosclerosis (Figure 1.8). FGF-2 
activity has generally been attributed to the activation of the intrinsic tyrosine kinase 
activity of its receptors. However, some study has indicated that FGF-2 can stimulate 
the dephosphylation of the cell surface HSPG syndecan-4, in the absence of its receptor. 
FGF-2 has been localized in the nervous system in a variety of species. In human 
adult brain, strong staining for FGF-2 is observed in central nervous system and in 
cerebellar Purkinje cells. In the adult brain FGF-2 immunoreactivity is observed in 
astrocytes, in selected neural populations, and occasionally in microglial cells. In the 
human adult brain, all FGF-2 isoforms are found (18-, 22-, 24 and 34kDa) (Nugent and 
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Iozzo, 2000). Several functions for FGF-2 in the nervous system have been proposed 
(i.e. regeneration of the oligodendroglial lineage after demyelination or a trophic role in 
the catecolamin cell groups of the rat brain). 
 
       Figure 1.8: Mechanisms of FGF-2 induced angiogenesis. 
In the lung, FGF-2 has been related with branching morphogenesis and development 
of pulmonary fibrosis (Han et al., 1992, Hetzel et al., 2005) 
FGF-2, as well as several other FGF family members such as FGF-4 and -8, 
stimulates limb development. It is, however, unlikely that FGF-2 is the prime candidate 
for limb formation as its expression pattern does not correlate with the tempor-spatial 
events occurring during limb generation. FGF-4 and -8 seem to be better candidates for 
endogenous limb-forming molecules (Olwin et al., 1994). 
Development studies indicate that FGF may play an important role in muscle 
development. Disruption of FGF signaling by expression of a dominant negative 
FGFR2 result in gastrulation defects that are reflected in the lack of formation of the 
notochord and muscle (Utton et al., 2001). Even in embryos that show mild defects, 
muscle formation is impaired.   
The proliferation, differentiation and TGF-β production of osteoblasts are stimulated 
by FGF-2 (Devescovi et al., 2008) 
FGF-2 modulates basal and LH/human choriogonadotrphin (LN/hCG)-stimulated 
Leydig cell function (Laslett et al., 1997)  
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Several functions have been proposed for ocular FGF-2: (i) induction of retinal 
regeneration in vitro and protects photoreceptors from light damage, (ii) stimulation of  
lens epithelial cells to proliferate, migrate, and differentiate into fiber cells, (iii) 
proliferation of corneal endothelium (Wu et al., 2008). 
The proliferation and differentiation of normal human melanocytes and several 
activities of keratinocytes are dependent on FGF-2 production (Berking et al., 2001). 
1.2.3 Anti-angiogenic factors 
Angiogenesis inhibitors are substances that inhibit the growth of new blood vessels. 
Angiogenesis inhibitors can be endogenous including proteins or fragments of proteins 
that are formed in the body (Ribatti, 2009) or exogenous such as drugs or dietary 
components.  
1.2.3.1 Endogenous inhibitors of angiogenesis 
The main endogenous inhibitors of angiogenesis are included in Table 1.5. 
1.2.3.1.1 Angiostatin. 
Angiostatin, a 38 kDa specific inhibitor of endothelial cell proliferation, is an internal 
fragment of plasminogen containing at least three of the kringles of plasminogen 
(Persano et al., 2007). Angiostatin was isolated from subclone of Lewis lung carcinoma 
in which the primary tumor inhibited the growth of its metastases. Angiostatin, 
generated by the primary tumor, was demonstrated to potently inhibit angiogenesis. 
Really, systemic therapy with angiostatin led to the maintenance of metastases in a 
microscopic dormant state defined by a balance of apoptosis and proliferation of the 
tumor cells. 
Angiostatin inhibits EC migration and proliferation most likely through its ability to 
bind a cell surface ATP synthase, which may act as a receptor. Moreover, by inhibiting 
extracellular matrix (ECM)-stimulated plasminogen activation, it determines a decrease 
in endothelial cell invasion. Other studies revealed that angiostatin may induce 
apoptosis in EC, albeit at relatively high concentrations (Benouchan and Colombo 
2005). 
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Table 1.5. Types o endogenous inhibitors of angiogenesis. 
Origin  Type 
Matrix derived  Anastellin 
  Arresten 
  Canstatin 
  Endorepellin 
  Endostatin 
  Fibulin 
  Targeting fibronectin-binding integrins 
  Thrombospondin-1 and -2 
  Tumstatin 
Non matrix derived Growth factors and cytokines 
  Interferons 
  Interleukins 
  Pigment epithelium derived factor (PEDF) 
 Fragments of blood coagulation factors 
  Angiostatin 
  Antithrombin III 
  Platelet factor-4 
  Prothrombin kringle 2 
Others  2-Methoxyestradiol 
  Chondromodulin 
  Prolactin fragments 
  Soluble Fms-like tyrosine kinase-1 (S-Flt-1) 
  Tissue inhibitors of metalloproteinase (TIMPs) 
  Troponin I 
  Vasostatin 
 
1.2.3.1.2 Endostatin. 
Among the many inhibitors of angiogenesisis endostatin is one of the endogenous 
inhibitor that has been shown to inhibit the growth of a wide variety of tumors with no 
apparent toxic side effects. Of particular interest is the lack of acquired drug resistance 
exhibited by experimental cancers in mice when exposed to repeated doses of endostatin 
(O’Reilly et al., 1997).  
Endostatin is a 20 kDa C-terminal cleavage product of collagen XVIII which belongs 
to the multiplexin family and is characterized by multiple triple-helix domains and 
interruptions (Figure 1.9). 
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                        Figure 1.9. X-raycrystal structure of endostatin. 
The generation of endostatin from collagen XVIII is catalyzed by proteolytic 
enzymes such as cathepsin L and matrix metalloproteases (Heljasvaara et al., 2005). 
Like many other angiogenesis inhibitors, endostatin has an affinity for heparin. The 
crystal structure of endostatin reveals an extensive basic patch of 11 instances of 
arginine, which may serve as a binding site for heparin. This site has recently been 
shown to be involved in the inhibition of induced angiogenesis (Olsson et al., 2004). At 
the same time, heparin binding was not observed to play any role in the ability of 
endostatin to inhibit the migration of endothelial cells. Endostatin binds with low 
affinity to the heparin sulfate proteoglaycans, glypican-1 and glypican-4, and with high 
affinity to an unidentified molecule on endothelial cells. 
Other experiment has also shown that endostatin associate with proteins such as α5 
and αν integrins, fibulin, laminin-1 and tropomyosin. Furthermore, it has been reported 
that endostatin is internalized by endothelial cells, but not by mouse fibroblasts. 
Therefore, it is possible that endostatin may present its signaling directly in the 
cytoplasm without any need for a transducing member receptor. 
The physiological functions of endostatin are comparably diverse. Recent studies 
show that endostatin inhibits renal epithelial cell branching morphogenesis, and may 
play a role in the regulation of ureteric arborization (Van Hensbergen et al., 2002). 
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The ability of endostatin to inhibit tumor growth and angiogenesis in vivo is 
demonstrated by extensive studies performed on distinct animal models in numerous 
laboratories throughout the world. Recently, Kalluri’s laboratory could provide genetic 
proof that endostatin is an endogenous angiogenesis inhibitor and a tumor suppressor 
(Sund et al., 2005). When endostatin was knocked out, tumors grew 2-to 3-fold (200 to 
300%) faster than wild type mice. In contrast, when endostatin was over-expressed by 
only 1.6-fold increase of the circulating level to mimic individuals with Down 
syndrome, tumors grew 3-fold slower than the wild type mice. Finally, some work has 
convincingly shown that endostatin-deficient mice exhibited increased angiogenesis. 
Endostatin levels are elevated in certain types of cancer, in intratumoral fluid and 
malignant ascites and in chronic inflammatory diseases such as rheumatoid arthritis and 
diabetic retinopathy. 
1.3 Angiogenesis and helminthic diseases 
Although the investigation about angiogenesis and tumor come back nearly 100 
yearas ago, but there is existed a little information about the role of angiogenesis and 
angiogenic factors in helminthiasis, both in humans and in experimental models or 
laboratory studies. 
Angiogenic factors are produced either by the parasite or the host can stimulate 
neovascularization through a number of different mechanisms (Figure 1.10). As an 
example, has been demonstrated that nematode parasite C. elegans encodes a factor 
capable binding mammalian VEGF receptors and inducing angiogenesis (Tarsitano et 
al., 2006). This is named C. elegans pvf-1 gene that codifies a PDGF/VEGF-like factor 
with a biochemical properties similar to vertebrate PDGF/VEGF growth factors. More 
important, pvf-1 binds to the human receptors VEGFR-1 (Flt-l) and VEGFR-2 (KDR) 
and is able to induce angiogenesis. The mechanisms related with host molecules can be 
divided into three categories; first of all, may be more important, potent angiogenic 
proteins such as vascular endothelial growth factors (VEGF) and the fibroblast growth 
factor (FGF-2) induce angiogenesis directly, by stimulation of endothelial cell 
proliferation, migration and differentiation into vascular tubes. Second, other 
angiogenic factors, such as interleukin-1, promote angiogenesis indirectly by 
stimulating inflammatory cells to produce VEGF. And third, angiogenic proteins such 
as heparinase are proteolytically cleaved, and the released peptides stimulate 
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components of the host’s immune system, which in turn stimulate the production of 
other angiogenic factors such as VEGF and FGF-2 (Zcharia et al., 2001). Finally, some 
angiogenic factors stimulate other mechanisms involved in the final lesions. In fact, 
experimental data suggest that hypoxia in relation to VEGF may stimulate proliferation 
of synthesis of collagen type1 in activated myofibroblast-like rat hepatic stellate cells 
(Novo et al., 2007). They have shown VEGF and angiopoitin 1 (Ang-1) can operate as 
hypoxia-dependent, autocrine and paracrine factors able to stimulate nonoriented 
migration and chemotaxis of human myofibroblas-like rat hepatic stellate cells 
(HSC/MFs) through the activation of (Ras/Erk) signaling.  
 
                                Figure 1.10. Helminths and angiogenesis 
In practice, the main information about angiogenesis and angiogenic factors in 
helminthic diseases is limited to infections caused by Schistosoma spp, filarial, Taenia 
solium and Trichinella spp. 
Schistosomiases are infections caused by different species of the genus Schistosoma. 
With the exception of cercarial dermatitis and the Katayama syndrome, the pathogenic 
basis of schistosomiasis is the formation of granulomas around parasite eggs. 
Although information is scarce in the literature, we note that in the initial stages of 
schistosomiasis, there is a stimulation of angiogenesis. Thus, it has been clearly 
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demonstrated by histological and immunohistochemical techniques the presence of 
angiogenesis in several experimental models of schistosomiasis (Farah et al., 2000; 
Botros et al., 2008; Baptista and Andrade, 2005). In this context is interesting to note 
several aspects: (i) angiogenesis is an early phenomenon, so in evolutionated phases 
(such as those has been found in humans) is hard to objectify (Baptista and Andrade, 
2005), (ii) an aspect importantly, demonstrated experimentally in the induction of 
angiogenesis, is the need for repeated exposure to the parasite (Farah et al, 2000) and 
(iii) genetic factors play an essential role in the angiogenic response to the parasite (Van 
de Vijver et al, 2006; Rutitzky et al., 2005). 
The mechanisms by which Schistosoma spp triggers angiogenesis are of various 
types and have been obtained in experimental studies. Thus, several studies have 
identified specific Schistosoma mansoni egg-derived regulatory molecules that include 
lysophosphatidylserine and prostanoids. Also eggs secrete/excrete additional factors that 
are capable of stimulating endothelial cell proliferation, migration, p42/44 MAPK 
phosphorylation and cell sprouting directly. The effect of this factor is not restricted to 
endothelial cells, but also stimulated vascular smooth muscle cells (Kanse et al., 2005). 
On the other hand, Schistosoma mansoni soluble egg antigen (SEA) promotes 
proliferation, increased tube formation, decreased apoptosis and increased 2-fold 
messenger RNA for vascular endothelial growth factor (VEGF) of human umbilical 
vein endothelial cells (HUVECs) (Loeffler et al., 2002) These findings suggest that 
products secreted by schistosome eggs may promote angiogenesis within hepatic 
granulomas by up-regulating endothelial cell VEGF. Moreover, Schistosome eggs, 
attached to endothelium (Pearce et al., 2004) indirectly promote angiogenesis through 
hypoxia and inflammatory response. The main host-derived initiators of this 
inflammatory response  include the early inflammatory cytokine, tumor necrosis factor-
α (TNF- α) and the endothelial cell-adhesion molecule, intercellular adhesion molecule-
1 (ICAM). At later stages, is developed periportal fibrosis by a mechanism that primes 
lymphocytes to produce increased levels of profibrotic molecules that include TGF-β 
and IL-4 (Farah et al., 2000). Finally, extravasation of the egg into the surrounding 
tissue and disruption of the portal stroma causes the migration of inflammatory cells to 
the site of egg deposition (Silva et al., 2006). The pre-existing portal stroma, showing 
normal CD34-immunoreactivity, is disrupted completely in and around the granulomas 
and is only preserved closely near to the portal vein and bile duct. Modulation of 
basement membrane components, proteoglycans, collagens and fibronectin imbalance 
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the connective stromal tissue matrix, has been described previously in schistosomal 
granulomas (Jacobs et al., 1998). Proteolysis of the dense extracellular matrix by 
collagens and matrix metalloprotinases (MMPs), a process preceding angiogenesis, 
seems necessary to allow the development of larger inflammatory reaction.While the 
endothelial cell proliferation fraction of a quiescent mature vasculature is 0.01% 
(Carmeliet and Jain, 2000), the presence of multiple proliferating cells in each 
granuloma shows the dynamic angiogenesis in schistosome induced inflammation. 
At our knowledge, only two groups have studied the role of angiogenic factors in 
human schistosomiasis and their results are hardly comparable. Thus, Tawfeek GM et 
al., (2003) evaluate 90 patients with schistosomiasis related to S mansoni classified in 
five groups according to sonographic studies: infected lightly, infected heavily, 
intestinal, early hepatosplenic and periportal fibrosis. When compared with controls, 
they found that VEGF levels were significantly raised in all schistosomiasis patients 
groups except lightly infected and intestinal groups. Moreover, the level of VEGF 
correlated with disease progression from lightly infected to periportal fibrosis patients. 
Using a different study design, Toledo and colleagues measured serum levels of VEGF 
in patients with schistosomiasis with or without portal hypertension (de Toledo et al., 
2009). These authors found no significant differences between both groups, although 
the average values in the group with portal hypertension were younger, a fact that 
coincides with low levels of VEGF detected in patients with cirrhosis from other causes 
(Shi et al., 2001). 
Filariasis is diseases related with the infection of several genus and species of 
nematodes (Wuchereria bancrofti, Brugia malayi, Brugia timori, Onchocerca volvulus, 
Loa loa, Mansonella perstans, Mansonella ozzardi and Mansonella streptocerca). 
Altered angiogenesis has been described in only two types of filarial diseases: 
lymphatic filariasis (Pfarr et al., 2009) and onchocerciasis.  
Clinical lymphatic filariases (and specifically infections related with W. bancrofti) 
are characterized with lymphoedema, lymph vessel dilation, lymph extravasation and, in 
some cases, the development of elephantiasis. There is some evidence of the role of 
angiogenic factors (and specifically of the family of VEGF) in the pathogenesis of 
lymphatic filariasis. Thus, in a longitudinal study in 63 Polynesian patients living in an 
hyperendemic focus of W. bancrofti, chyluria was associated with increased vascular 
endothelial growth factor (VEGF) levels, whereas elephantiasis presented a high 
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endothelin-1 (ET-1) profile (Esterre et al., 2005). On the other hand, host genetics is 
related with the clinical evolution of lymphatic filariasis. Specifically, in a cohort of 
lymphatic filariasis patients from Ghana, three VEGF-A promoter polymorphisms were 
examined (Debrah et al., 2008). The authors found that C/C genotype at -460 was 
significantly higher in hydrocele patients and in patients with high serum VEGF levels. 
Finally, in a cohort of bancroftian filariasis in Ghana, serum VEGF-C and sVEGFR-3 
were elevated at basal evaluation (Debrah et al., 2006). Doxycycline-treated patients 
(for Wolbachia spp eradication) decrease VEGF-C and sVEGFR-3 at a level close to 
that of endemic normal values, with amelioration of supratesticular dilated lymphatic 
vessels and with an improvement of lymphatic pathology. 
Onchocerciasis is characterized by two types of clinical manifestations: subcutaneous 
nodules (macrofilarial-related) and skin and ocular lesions (microfilarial-related). O. 
volvulus nodules in perfusion studies have different patterns of angiogenesis (Smith et 
al., 1988). Small nodules had an extensive blood supply, diffusely distributed 
throughout the nodule matrix, and in close association with the coils of the worms. In 
bigger nodules the central area appeared more dense, and intense vascularization 
appeared to be more peripheral; in the largest nodules the central core was not well 
vascularized, but a band of heavy vascularization was seen at the margin of the core, fed 
by superficial vessels and in close contact with worm coils. At least one derived O. 
volvulus protein (Ancylostoma secreted protein homologue) can contribute to abnormal 
angiogenesis (Higazi et al., 2003) 
Neurocysticercosis is a common central nervous system (CNS) infection caused by 
Taenia solium metacestodes. In this infection is well-documented the importance of the 
granulomatous response in their pathogenesis. A small series of eight patients with 
neurocysticercosis subjected to craniotomy for histological and immunohistochemical 
analysis, shows dying parasite surrounded by a mature granuloma with associated 
fibrosis, angiogenesis and an inflammatory infiltrate. The most abundant cell types were 
plasma cells, B and T lymphocytes (Th1), macrophages, and mast cells (Restrepo et al., 
2001). Moreover, an increased angiogenesis has been observed in animal models of 
neurocysticercosis (Sikasunge et al., 2009). 
Trichinellosis is a nematode infection in which primarily affects striated muscle 
cells. Larvae of Trichinella spp initiate the transformation of myocytes into nurse cells 
that become surrounded by elaborate networks of blood vessels. In mice experimentally 
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infected by Trichinella spp several vessel abnormalities were detected (Baruch and 
Despommier, 1991). Thus, vascular complexes were found only around infected 
myocytes and were characterized by large circumferential vessels that give rise to the 
smaller channels of the retes. The secondary vessels vary widely in caliber and are 
distributed in a random fashion. Three types of network were found: simple, complex, 
and hypercomplex, and they were distributed normally, with the complex retes the most 
common. Comparison of the structure of the baskets with that of vessels in surrounding 
uninfected muscle strongly suggests that the vascular retes are the result of de novo 
angiogenesis induced during the infection. In this setting, excretory/secretory products 
of larval T. spiralis and T. pseudospiralis have been related with degenerative/ 
regenerative muscular changes and angiogenesis (Ko et al., 1994). 
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In the previous review we observed that: (i) angiogenesis is an important process of new 
blood vessel formation not only in tumor diseases but also in the pathogenesis of other 
diseases, specifically due to helminths (ii) studies on the role of angiogenesis in disesases 
due to helminths are scarce (iii) there is no bibliographical information on the production of 
angiogenic factors by macrophages or the use of anti-angiogenic factors in helminth 
infections (iv) although it has demonstrated the role of nitric oxide in these diseases and 
there is a documented relationship between nitric oxide and VEGF and other angiogenic 
agents, there is no specific bibliographical information about the interaction of both 
inflammatory mediators in these parasitic diseases. 
 
The objectives proposed in this Thesis doctoral are: 
1 .- To evaluate the expression of angiogenic factors (VEGF and FGF2) in alveolar 
macrophages stimulated with different antigens from different stages of the life cycle of 
Trichinella spiralis, Trichinella pseudospiralis, Strongyloides venezuelensis and 
Schistosoma mansoni. 
2. - To study the relationship between the expression of angiogenic factors and nitric 
oxide production using specific inhibitors of inducible nitric oxide synthase. 
3. - Using in vitro models of helminth infections to evaluate the effect of anti-angiogenic 
factors (endostatin). 
4. - Using experimental models of infection the strongyloidosis S. venezuelensis and 
schistosomiasis by Schistosoma mansoni to evaluate the effect of anti-angiogenic factors in 
the development of the disease, studying the mechanisms that may be involved. 
5. - To analyze the production of angiogenic factors in sera of patients diagnosed with 
imported diseases due to helminths. 
3 Investigation articles 
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Abstract 
Background: Angiogenesis is the process of new blood vessel formation, has an 
important role in various processes, including cancer and inflammation. Schistosomiasis is a 
helminthoses that affects more than 200 million people in the world. Previous works have 
demonstrated that soluble antigens of Schistosoma mansoni induced angiogenesis by up-
regulation vascular endothelial growth factor (VEGF) in human endothelial cells. The 
objectives are: (i) to study VEGF in sera of patients diagnosed of schistosomiasis and other 
helminthoses (ii) to evaluate the effect of endostatin (angiogenesis inhibitors) in mice 
infected with S. mansoni (iii) to detect VEGF and fibroblast growth factor (FGF2) 
expression in macrophages stimulated with S. mansoni antigens. 
Methodology/Principal Findings: VGEF protein was detected in sera of healthy 
patients, patients diagnosed of schistosomiasis, filariasis and hookworms infections. Patient 
diagnosed with schistosomiasis only showed significant differences in VEGF level in 
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compared with healthy patients. Uninfected group, mice infected with S. mansoni and mice 
infected and treated with endostatin were used. Parasitological, analytical data and IgG, 
IgG1 and IgG2a specific antibodies were analyzed. VEGF and FGF2 expression were 
detected by RT-PCR in liver and intestine. Mice treated with endostatin showed significant 
differences in eggs recoveries from liver and IgG2a antibodies detection in compared with 
infected mice group. Finally, the effects of the cercarial and adults S. mansoni antigens on 
the VEGF and FGF2 stimulation were evaluated. Macrophages were obtained by 
bronchoalveolar lavage (BAL) from Wistar rats. Cells were cultured at different 
concentrations of antigens (0.1-50 µg/ml), and their expression were determined by RT-
PCR. Cells stimulated with 50µg/ml of cercarial S .mansoni antigens expressed VEGF and 
FGF2. 
Conclusion/Significance: These finding may suggest the important role of angiogenic 
factors in the pathogenesis of schistosomiasis. 
 




Schistosomiasis is one disease produced by helminths which affect many people in 
tropical areas. Except of acute phase (cercariae dermatitis and Katayama fever), granuloma 
formation is the principal mechanism involved in the pathogenesis of this disease. 
Experimental studies have demonstrated angiogenesis (blood vessels formation from pre-
existing vessels) in the initial phase of granuloma formation. In the present work, firstly the 
level of the main pro-angiogenic factors (vascular endothelial growth factor) were analyzed 
in sera from people diagnosed with schistosomiasis. We observed significantly high levels 
of this angiogenic factor in patients with schistosomiasis in compared with healthy people 
and patients diagnosed with other helminthic infections. In addition, we evaluated in 
experimental schistosomiasis murine model the effect of angiogenesis inhibition using anti-
angiogenic factors (endostatin). A lesion decrease was observed in mice pre-treated with 
endostatin and infected with Schistosoma mansoni. Finally, mechanisms of angiogenesis 
induction were studied and observed that cercariae antigens stimulated the angiogenic 
factors (vascular endothelial growth factor and fibroblastic growth factor-2) by host alveolar 
macrophages. 
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Introduction 
Schistosoma mansoni is one of the blood flukes there are to intravascular typical 
residence in the pelvic or mesenteric veins of the host. The female adult worms produce 
hundreds to thousands of eggs per day. Each ovum contains to ciliated miracidium larva, 
which secretes proteolytic enzymes that help the eggs to migrate into lumen of the bladder 
or the intestine [1]. Early pathological changes arise after mechanical occlusion of the 
microvasculature by the eggs causing acute vasculitis with endothelial damage and necrosis. 
Granuloma formation results from a delayed hypersensitivity response generated by the host 
against antigens secreted by the parasite eggs [2]. In initial phases the inflammatory 
response is intense with important neovascularization. Moreover, fibrosis was produced in 
later phases and it was responsible of the pathological disorders of this disease [3]. 
However, considerable variations in the magnitude of the disease have been described 
among different hosts and specifically among different mouse strains [4]. 
Angiogenesis, the formation of new endothelial vessels from pre-existing post-capillary 
venule, is a characteristic feature of inflammatory diseases, wound repair and cancer [5]. 
The angiogenic activity depends on the balance or imbalance between angiogenic and 
angiostatic mediators. Remodelling and degradation of the surrounding stroma is essential 
to start to an angiogenic phenotype. These stromal changes facilitate recruitment and 
activation of leucocytes, fibroblast and endothelial cells. While granulomas are traditionally 
considered to be avascular structures, schistosome granulomas should be seen as an 
inflammatory condition that initiates a variable degree of wound healing response in which 
angiogenesis and fibrosis are highly involved [6]. 
The aim of this work was to evaluate the role of angiogenic factors in the pathogenesis of 
schistosomiasis. Firstly, vascular endothelial growth factor (VEGF) detection in sera of 
patients diagnosed of schistosomiasis and other helminthic diseases were studied. Secondly, 
the effects of endostatin (angiogenesis inhibitor) in mice infected with Schistosoma mansoni 
were analyzed. Finally, VEGF and fibroblastic growth factor (FGF2) expression from 
alveolar macrophages stimulated with different S. mansoni antigens were analyzed. 
Methods 
Human population  
The study group was formed by 53 patients from sub-Saharan areas with eosinophilia 
(≥450 eosinophil/µl). They had recently arrived in Canary Island of Spain. They have been 
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living in Spain since 6 months ago and have been diagnosed only by one parasite as shown 
in Table 1. All patients were diagnosed by direct parasitological tests included: (i) 
Coprology in 3 stool samples for ova and parasites by using Kato-Katz and Ritchie 
techniques, (ii) Identification of Schistosoma haematobium by examination of urine for eggs 
with sedimentation, (iii) Knott’s test for detection of microfilaremia in blood and (iv) 
Immune chromatographic test (ICT Filariasis, Binax, Portland and Maine) for the detection 
of Wuchereria bancrofti. 
Healthy control group was formed by immigrants from the same geographic area as 
patients of the study group. We have done for all clinical examination, a systemic analytical 
study and also parasitological tests and direct serological examination. In all cases the 
control group, there were not detected eosinophilia and presence of parasite. 
 
Parasite and antigens 
BALB/C mice were maintained under standard conditions in an environment with 
controlled temperature and humidity with 12 h light/dark cycle and free access to water and 
food. Schistosoma mansoni cercariae were obtained from Biomphalaria glabrata snails 
previously infected with S. mansoni miracidia [7]. Mice were sacrificed on the 7 week post-
infection (pi) and adult worms were recovered from the hepatic portal and mesenteric veins 
by perfusion technique[8]. 
Adult worm antigen (AWASm) and cercarial antigen (CSm) from S. mansoni were used 
accordance with Dunne et al[9]. Briefly, S. mansoni worms were recovered by portal 
perfusion buffer. Recovered worms were washed free of erythrocytes and then snap frozen 
in liquid nitrogen. Frozen worms were ground into a paste, allowed to thaw and then 
centrifuged at 10,000g at 4ºC for one hour. After that 1mM N-Tosyl-1 phenylalanine 
chloromethyl ketone and 1mM Phenyl-methylphonylfluride (Sigma Chemical Co, St 
Louise, MO) were added. The soluble material was centrifuged, filtered through a 0.22 µm 
sterile filter and then stored at −80ºC. Cercarial antigen (CSm) was obtained from cercariae 
harvested within three hours of being shed from snail, snap frozen in liquid nitrogen and 
then processed identically to adult worm antigen. 
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VEGF detection in human samples  
The determination of VEGF was realised in serum from human samples by ELISA 
technique (Vascular Biotrak Endothelial Growth Factor [(h) VEGF] human ELISA System, 
GE Healthcare Buckinghamshire, UK) accordance with manufacture instructions. 
Mice experimental design 
Three groups of six-weeks-old CD1 mice weighing 16-25 g were used as follows: 
uninfected group, mice infected with 150 S. mansoni cercariae per animal, mice infected 
with 150 S. mansoni cercariae and treated with 2.5 mg/kg of endostatin (Sigma) at 36, 38, 
40 and 42 days post-infection[10]. From these animals’ sera and blood samples were taken 
weekly from week 0 to 7 after challenged. 
Animals were sacrificed at week 7 post-infection (pi) and the following parasitological 
parameters were assessed: (i) number of worms after liver perfusion, (ii) number of eggs per 
gram of liver, and (iii) number of eggs per gram of intestine, , and (iv) number of 
granulomas on liver surface counted under a stereoscopic microscope. In addition, from all 
animals liver and intestine were harvested and adult worms were collected and counted. 
Blood samples were obtained and these samples were used for ELISA techniques and 
analyzed on hemocytometer Hemavet 950 (Drew Scientific Group).  
ELISA technique was performed by detection of IgG, IgG1 and IgG2a in mice infected 
with Schistosoma mansoni and treated with endostatin. Briefly, 96-well polystyrene plates 
(Costar) were coated with 5 µg/ml of S. mansoni AWA antigen diluted in carbonate buffer 
pH 9.6. Serum were added at 1:100 dilutions and incubated for 1 hour at 37ºC. Horseradish 
peroxidase rabbit anti-mouse IgG, IgG1 and IgG2a (Sigma, St. Louis, MO.) at 1:1.000 
dilution was added. After incubation for 1 hour at 37ºC, substrate solution (ortho-phenylene 
diamine plus H2O2) was added, and the reaction was stopped at 10 minutes with 3 NH2SO4. 
Absorbances were measured at 492 on an Ear400FT ELISA reader (Lab Instruments). The 
results are expressed as means of the optical density from all the animals of each group plus 
the standard error. 
VEGF and FGF2 expression in mice infected with S. mansoni by RT-PCR 
Total RNA isolated from liver or intestine of all mice were used to analyze the 
expression of VEGF and FGF2 by RT-PCR as described previously (Shariati et al., in 
press)[11]. Briefly, total cellular was isolated with the Rneasy Mini Kit (Qiagen GmbH, 
Hilden Germany), according to manufactures instructions. Resulting RNAs were reverse 
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transcribed with the First Strand cDNA Synthesis kit (Roche), according to manufactures 
instructions. Primers specific for rat VEGF were sense, 5´- 
CTGCTCTCTTGGGTGCACTGG-3´ and anti-sense, 5´- CACCGCCTTGGCTTGT 
CACAT-3´. VEGF-PCR reaction were carried out through reverse transcription incubation 
at 94ºC for 5 min, 35 cycles of 94ºC for 1 min, 55ºC for 1 min, 72ºC for 1 min and a single 
cycle at 72ºC for 7 min. Primers specific for detection of FGF2 were sense, 
5´GCCGGCAGCATCACTTCGCT-3´ and anti-sense, 5´CTGTCCAGGCC CCGTTTTGG-
3´. FGF2-PCR reaction were carried out through reverse transcription incubation at 94ºC for 
2 min, 50 cycles of 94ºC for 30 seconds, 60ºC for 30 seconds, 72ºC for 1 min and a single 
cycle at 72ºC for 5 min. PCR product were analyzed by electrophoresis in agarose gel 
stained with ethidium bromide with glyceraldehydes 3-phosphate dehydrogenase (GAPDH) 
as internal control. Primers specific for (GADPH) were sense, 5´-
GGTCGGTGTGAACGGATTTG-3´ and GAPDH anti-sense, 5´-
GTGAGCCCCAGCCTTCTCCAT -3´ that were used as positive control[11]. 
VEGF and FGF2 expression in alveolar macrophage stimulated with different antigens 
of Schistosoma mansoni  
Macrophages were obtained from male Wistar rats of 250-300g by bronchoalveolar 
lavage (BAL) as previously described[12]. Rats were euthanized with an intraperitoneal of 
sodium pentobarbital (100 mg/kg bw). Lungs were lavaged with aliquots of 5 ml of sterile 
phosphate-buffered saline (PBS, pH 7.4) using sterile Teflon catheter (VYCON Code 
123.06, lot 220987, Vigon, Spain) for collection of BAL fluid. The fluid was immediately 
withdrawn by gentle suction. Lavage fluid was collected in 50 ml tubes and centrifuged at 
1000g at 4ºC temperature to pellet the cells. 
The cells were suspended in 1 ml fresh complete medium containing 44 ml of Dulbecco's 
Modified Eagle Medium (DMEM), 2 mM glutamine, 10% heat inactivated fetal bovine 
serum (FBS) and antibiotic solution[(with 10,000 units penicillin and 10 mg streptomycin 
per ml) (Sigma Chemical Co, St Louise, MO)]. Viability of cells was estimated by the 
mitochondrial reduction of MTT (3-[4, 5-dimethyl-thiazol-2-yl]-2.5-diphenyl tetrazlium 
bromide) (Sigma) to formazan which was found to be more than 87.5% accordance with 
Andrade et al [13]. Cells were then counted, seeded in a 12-Well Cell Culture Cluster 
(Corning, NY 14831 USA) at the density of 1×106 cells/well and incubated at 37 ºC in 5% 
CO2 incubator (RS Biotech, Galaxy). After 2 h, non-adherent cells were washed away with 
sterile PBS and adherent cells (macrophages) were incubated in fresh complete medium. 
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Cells were treated with a dose of 10 µg/ml lipopolysaccharide (LPS; Sigma; positive 
control) and 0.1-50 µg/ml of S mansoni antigens (AWASm and CSm). Non-stimulated 
macrophages were used as negative control. All experiments were performed in triplicate. 
Total RNA was extracted from alveolar macrophages using an RNeasy Mini Kit (Qiagen 
GmbH, Hilden Germany.). A total of 1µg RNA was used as template for the first-strand 
DNA synthesis. Primers specific and PCR reactions for VEGF, FGF2 and GAPDH were 
done as above. 
Ethics Statement 
The HUIGC (Hospital Universitario Insular de Gran Canaria)-IRB approved an oral 
consent process that included a written summary and a short form. The oral presentation and 
the short form were made in a language understandable to the subject. The interpreter 
(witness) was fluent in both the language of the participant and the language of the consent. 
The written summary was signed by the 1) witness and 2) person obtaining consent. The 
short form was signed by the 1) witness and 2) the participant or participant’s legally 
authorized representative. 
Mice were housed and handled under standard animal laboratory conditions according to 
the EU regulations. All animal procedures were approved by the University of Salamanca 
Animal Care and Committee. 
Statistical analysis 
Data of VEGF in human sera, number of eosinophils and epidemiological data of human 
population were reported as mean ± standard deviation (SD). Linear regression was 
performed with INSTAT programme. The overall differences among groups were compared 
by non-parametric Kolmogorov-Smirnov analysis. Data of parasite recovery, eggs per gram 
of liver or intestine in mice, blood cells and serological data were reported as mean ± SD. 
Differences in mice groups were performed by analysis of variance (ANOVA). When global 
differences were detected a post-ANOVA test using the Fisher least significant differences 
(LSD) analysis was applied. Differences between means were considered statistically 
significant at p<0.05. All statistical analyses were performed using Statworks, Statview 4.5 
and INSTAT software packages for an IBM computer.  
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Results 
Evaluation of VEGF detection protein in human population  
Result showed significantly differences in VEGF detection protein between patients with 
schistosomiasis and healthy control patients (p< 0.05) (Table 1). Also, no differences were 
found between patients infected with S. mansoni and S. haematobium. Moreover, it was not 
observed any differences between patients diagnosed with other helminthoses (filariasis and 
hookworms infections) and healthy control patients. In addition, association between VEGF 
detection protein and number of eosinophils were not observed (Figure 1).  
Evaluation of the effects of endostatin on Schistosoma mansoni infection in a murine 
experimental model 
We studied the number of parasite recovery and eggs per gram in liver and intestine 
separately counted on day 46 post-infection. The mean number of worms recovery is 6.67 ± 
0.5 in mice infected with S. mansoni and 5.5 ± 0.6 in mice infected and treated with 
endostatin. Although the parasite recovery in infected group with S. mansoni were higher 
than mice treated with endostatin, these differences were not statistically significant. The 
mean number of eggs per gram in liver in the group of infected animals was significantly 
higher (p<0.05) than mice treated with endostatin (Figure 2). Moreover, the mean number of 
eggs per gram in small intestine in mice infected was higher than mice treated with 
endostatin but differences were not significant (Figure 2). We also studied the number of 
granulomas from liver in S. mansoni mice infected compared with mice treated with 
endostatin. The results showed that the mean number of granulomas in mice infected group 
was significantly higher than mice treated with endostatin (p< 0.05) (Figure 3).  
Red blood cells and platelet counts did not show any difference between groups. Only 
there was existed an increasing of the number of eosinophil in mice infected with 
S. mansoni (0.112±0.032) in compared with mice treated with endostatin (0.065±0.023) but 
differences was not significant (data not shown). 
Specific IgG, IgG1 and IgG2a S. mansoni antibodies are shown in Figure 4. Specific IgG 
and IgG1 S. mansoni antibodies had not reduction between S. mansoni infected group and 
mice treated with endostatin. On the other hand, IgG2a antibodies detection presented 
statistical differences (p< 0.05) in mice infected and treated with endostatin. 
RT-PCR in liver showed that VEGF-mRNA expression decreased in mice treated with 
endostatin in comparison with mice infected with S. mansoni (Figure 5). Similarly, FGF2 
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expression in liver also decreased in mice treated with endostatin in comparison with mice 
infected with S. mansoni (Figure 5). In contrary, VEGF and FGF2-mRNA expression in 
intestine did not show differences between S. mansoni infected group and mice treated with 
endostatin (Figure 6). 
Evaluation of the effects of Schistosoma mansoni antigens on the VEGF and FGF2 
production by rat alveolar macrophages  
We studied the effects of different concentrations of different antigens of S. mansoni 
(0.1-50µg/ml) on the VEGF and FGF2 expression in alveolar macrophages (Figure 7). The 
result indicated that macrophages stimulated with 50µg/ml of cercarial antigen of S. 
mansoni (CSm) were able to induce VEGF and FGF2 mRNA expression (Figure 7A). On 
the other hand, macrophages stimulated with adult worm antigens of S. mansoni (AWASm) 
were not able to produce VEGF and FGF2 angiogenic factors (Figure 7B).  
Discussion 
The main helminthoses that affect the human population are geohelmintosis, 
schistosomiasis and filariasis[14]. These same worms also are responsible for parasitic 
infection in immigrant patients asymptomatic with absolute or relative eosinophilia [15, 16]. 
In the present work we evaluated VEGF concentration in the sera of patients with 
parasitological diagnosis of schistosomiasis, filariasis and hookworms infections. We 
selected patients from sub-Saharan Africa with eosinophilia who showed the presence of a 
single worm, not co-infection. We found that patients diagnosed of schistosomiasis had a 
high level of VEGF in sera compared with healthy patients group. These results are similar 
to those reported by other authors in S. mansoni infections [17]. We observed that there 
were no significant differences between VEGF levels in patients with schistosomiasis 
produced by S. mansoni and S. haematobium. Angiogenesis plays a fundamental role in 
many physiological and pathological processes, including the development of hepatic 
fibrosis. In cirrhosis, blood serum levels of VEGF are decreased[18]. However, high VEGF 
levels were detected in sera of patients with schistosomiasis, although controversial results 
were found in the VEGF detection among the different clinical phases of schistosomiasis 
[17, 19]. In addition, we observed that eosinophils are not involved in the expression of 
VEGF in humans because there was no association between number of eosinophils and 
VEGF detection in different helminthoses.  
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Secondly, we studied the effects that occur after inhibition of angiogenic factors in a 
experimental murine model of S. mansoni. We use endostatin as a specific inhibitor of 
angiogenesis[20]. The results showed that there was not significant reduction in the number 
of adult worms in mice infected with a significant reduction in the number of eggs in liver 
and number of granulomas in mice treated with endostatin compared with S. mansoni 
infected mice. This indicates that the inhibition of angiogenesis induced a decreasing of 
injury characteristics trigger hepatic formation of the granuloma and subsequent fibrosis. 
Moreover, we studied the mechanisms involved in the reduction of injury. Firstly, we 
analyzed data of the blood cells count (red, white blood and platelet cells). No significant 
differences in count of blood cells (specifically in eosinophils) were found between S. 
mansoni infected mice and mice treated with endostatin. The results obtained in this 
experiment are consistent with observations in count of eosinophils in human population 
infected with schistosomiasis, filariasis and hookworm infections. This is opposite to that 
found by our group when we analyzed the relationship between angiogenesis and 
strongyloidiasis (paper in press). Secondly we proved the decreasing of the expression of 
VEGF and FGF2 in liver. This data showed the effective inhibition realised by endostatin. 
Thirdly, we analyzed the immune response produced in mice infected and treated with 
endostatin. We found a decreasing significantly in the detection of specific IgG2a 
antibodies. This is associated with down-regulated Th1 responses in animals treated with 
endostatin which the reduction of number of eggs and granulomas in liver were observed. 
These results agree with observations by other authors in which severe schistosomiasis is 
associated with persistently elevated pro-inflammatory T-helper-1 (Th1)-type cytokines, 
whereas milder pathology is present when Th2 cytokines dominate [21]. Moreover, shift 
toward Th1-type cytokine production by a numerically stable population of CD4 T cells 
correlates with severe exacerbation of immunopathology in schistosomiasis [22].  
Finally, the last objective of our study was to identify S. mansoni antigens involved in the 
expression of VEGF and FGF2 angiogenic factors by alveolar macrophages. We used 
cercarial (CSm) and adult worms (AWASm) S. mansoni antigens. Our results showed that 
cercarial antigens were able to stimulate alveolar macrophages to produce VEGF and FGF2 
factors. Our results and the data obtained by Loeffler et al[23] where products secreted by 
Schistosoma eggs may promote angiogenesis within hepatic granulomas by up-regulating 
endothelial cell VEGF, shown the role of angiogenesis in schistosomiasis and its 
participation in the granulomatous reaction associated to the injury produced. 
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In summary, this study show the role of angiogenesis in the pathogenesis of 
schistosomiasis based on three aspects: (i) VEGF detection in patients diagnosed of 
schistosomiasis, (ii) reduction of eggs recovery and granuloma formation in liver in mice 
treated with endostatin with down-regulated Th1 immune response (iii) cercarial antigen of 
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Figure 2: Determination of S. mansoni eggs in liver and intestine. Mice were 
divided in two groups. (i) mice infected with S. mansoni and necropsy 7 week pi 
and (ii) mice infected with S .mansoni and treated with endostatin, necropsied 7 










Figure 3: Number of granulomas on liver surface. Hepatic granulomas on liver 
surface/cm2 were counted in two groups. (i) mice infected with S. mansoni and 
necropsy 7 week pi and (ii) mice infected with S .mansoni and treated with 
endostatin, necropsied 7 week pi. The results are expressed as mean ± standard 
error. An illustration of liver granulomas of treated and untreated control group 
is shown.* p<0.05. 
 
 







Figure 4: Detection of IgG, IgG1 and IgG2a specific antibodies by ELISA. Sera 
of three groups as (i) uninfected mice (ii) mice infected with S. mansoni (iii) 
mice infected with S .mansoni and treated with endostatin were analyzed. IgG 
(white colour), IgG1 (black colour) and IgG2a (grey colour) *p<0.05. 
 






Figure 5: Detection of VEGF and FGF2 by RT-PCR in liver. Three 
experimental groups were used: (i) uninfected mice (ii) mice infected with S. 
mansoni (iii) mice infected with S .mansoni and treated with endostatin. VEGF 
was expressed as three bands and arbitrary units (AU) calculated by 
densitometry of each band 601 bp (white bars), 540 bp (grey bars), and 408 bp 
(black bars). FGF2 expression showed a band with 423bp (white bars) and 
densitometry analysis of it as arbitrary unit (AU). GAPDH expression was used 
as internal control. 
 
 








Figure 6: Detection of VEGF and FGF2 by RT-PCR in intestine. Three 
experimental groups were used: (i) uninfected mice (ii) mice infected with S. 
mansoni (iii) mice infected with S .mansoni and treated with endostatin. VEGF 
was expressed as three bands and arbitrary units (AU) calculated by 
densitometry of each band 601 bp (white bars), 540 bp (grey bars), and 408 bp 
(black bars).FGF2 expression showed a band with 423bp (white bars) and 
densitometry analysis of it as arbitrary unit (AU). GAPDH expression was used 
as internal control. 
 









Figure 7: Effect of Schistosoma mansoni antigens on VEGF and FGF2 in 
alveolar macrophages. mRNA expression in rat alveolar macrophages 
stimulated with cercarial antigen of S. mansoni (A),, and adult worm S. mansoni 
antigen (B). GAPDH mRNA expression levels from rat macrophages detected 
by RT-PCR are used as internal positive control (C). Non-stimulated, negative 
control (Ø), LPS stimulated macrophages, positive control (LPS) and different 
concentrations of S. mansoni antigens, 0.1-50µg/ml. Arbitrary units are 
calculated by densitometry of corresponding amplicons. 
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4 Conclusions 
Conclusions  -92- 
 
1. - The antigens of encapsulated species Trichinella spiralis are able to stimulate in a 
dose-dependent manner, angiogenic factors (VEGF and FGF2) in rat alveolar macrophages. 
2. - Angiogenesis plays an important role in primary infection by Strongyloides 
venezuelensis, as its inhibition by using endostatin causes a decrease in magnitudes of 
infection. 
3 .- The endostatin reduces infection of Strongyloides venezuelensis not by direct action 
on the parasite but through indirect effects such as decreased production of angiogenic 
factors by host and / or reduction of the eosinophilic response. 
4. - The larval somatic antigens of Strongyloides venezuelensis are responsible for the 
induction of angiogenic factors and their modulation is related to the generation of nitric 
oxide. 
5. - In patients with schistosomiasis there is an increased VEGF levels in serum with 
significant differences compared with other diseases due to helminths. 
6. - Inhibition of angiogenesis by endostatin in murine experimental schistosomiasis 
induces a decrease in the number of eggs in liver, as well as in the presence of granulomas 
and hepatic fibrosis. 
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5 Resumen en español 
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El conocimiento sobre el control de la angiogénesis ha sido un gran avance en la 
comprensión de la patogénesis de muchas enfermedades en las últimas décadas. Los 
estudios sobre el papel de los factores angiogénicos y antiangiogénicos en la biología del 
crecimiento neoplásico, crecimiento del tumor y el desarrollo de las metástasis, son los más 
abundantes en la literatura. Sin embargo, tanto la generación como la inhibición de nuevos 
vasos desempeñan un papel importante en otros procesos fisiopatológicos, por ejemplo 
isquemia, infección e inflamación. La revisión bibliográfica de esta Tesis Doctoral está 
estructurada en tres secciones: en primer lugar analizamos los conceptos básicos de la 
angiogénesis y vasculogenesis, así como su papel en las enfermedades neoplásicas y no 
neoplásicas. En un segundo apartado estudiamos las características de los dos principales 
factores angiogénicos: VEGF (factor de crecimiento del endotelio vascular) y FGF-2 (factor 
de crecimiento de fibroblastos). Específicamente se indican las características estructurales 
de los factores y el mecanismo biológico de acción. Además, describimos factores 
antiangiogénicos como por ejemplo la endostatina, un potente inhibidor de la proliferación y 
migración. Por último, analizamos el papel de los factores angiogénicos y antiangiogénicos 
en la patogénesis de las helmintosis. Al respecto, hemos encontrado escasa información y 
limitada al estudio de la esquistosomosis, filariosis e infecciones por Taenia solium y 
Trichinella spp. 
Los vertebrados, incluyendo las especies de mamíferos, tienen un sistema de circuito 
cerrado para el suministro de nutrientes y oxígeno a los tejidos. Los vasos sanguíneos 
presentan dos tipos principales de células, células endoteliales que recubren el interior de los 
vasos y células del músculo liso que regulan la contracción y la dilatación de los vasos 
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sanguíneos. Desde el punto de vista embriológico, los vasos sanguíneos tienen dos etapas 
principales: vasculogénesis (formación de vasos sanguíneos a partir de células precursoras) 
y angiogénesis (formación de vasos sanguíneos a partir de vasos preexistentes y de células 
del endotelio vascular). La angiogénesis desempeña un papel importante en diversos 
procesos fisiológicos y patológicos, incluyendo el desarrollo embrionario, la cicatrización, 
la inflamación y el crecimiento tumoral. Tanto la liberación no controlada de los factores 
angiogénicos como la alteración de la producción natural de los inhibidores de la 
angiogénesis, con la consiguiente modificación del equilibrio angiogénico, son responsables 
de la proliferación incontrolada de células endoteliales que tiene lugar durante la 
neovascularización en la angiogénesis tumoral y en enfermedades asociadas. 
Folkmann en 1971 propuso que el crecimiento de tumores y metástasis dependen de la 
angiogénesis y por tanto su bloqueo puede ser una estrategia para detener el crecimiento 
tumoral. En las etapas iniciales de los tumores malignos hay un equilibrio entre la 
proliferación de células neoplásicas y su destrucción, tanto por apoptosis como por control 
inmunológico. Cuando el tumor primario alcanza un tamaño crítico, disminuye la 
concentración de oxígeno y las células producen factores angiogénicos. Por otra parte, la 
destrucción del tejido conduce a la producción de sustancias antiangiogénicas. La vida 
media de factores antiangiogénicos es mayor que el crecimiento tumoral y las metástasis en 
desarrollo. Sin embargo, cuando el equilibrio se altera a favor de la actividad pro-
angiogénica, la formación de nuevos vasos se lleva a cabo con las consecuencias que se 
indican en las secciones siguientes. Factores pro-angiogénicos incluyen varias moléculas 
liberadas por las células del parénquima o por células inflamatorias en respuesta a factores 
mecánicos, metabólicos (por ejemplo, hipoxia, acidosis) o respuesta inmune. Por otra parte, 
la destrucción del tejido conduce a la generación de moléculas con potencial 
antiangiogénico. El predominio de los factores angiogénicos conduce a la formación de 
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nuevos vasos sanguíneos a partir de precursores endoteliales locales y a partir de la médula 
ósea. 
En la angiogénesis tumoral están implicados tanto los vasos sanguíneos como los 
vasos linfáticos. Los vasos sanguíneos se pueden considerar anormales con respecto a la 
vascularización normal. Por lo tanto, macroscópicamente la distribución es muy 
desorganizada con dilatación de vasos tortuosos, con un diámetro irregular y un número 
excesivo de ramificaciones. Microscópicamente, el endotelio tiene numerosas aberturas con 
las uniones intercelulares ampliadas y la membrana basal discontinua o ausente. El músculo 
liso que rodea las células endoteliales no se contrae en respuesta a los estímulos normales, 
lo que limita el uso de vasoconstrictores en el tratamiento contra los tumores. Las 
principales alteraciones de los vasos linfáticos son la compresión de los vasos localizados en 
el tumor y la dilatación de los situados en la periferia por exceso de VEGF-C . Estos vasos 
linfáticos pueden recoger las células neoplásicas derivadas de la superficie del tumor y 
facilitar así la metástasis linfática. 
Las modificaciones vasculares descritas en la parte anterior determinan el flujo 
sanguíneo caótico intratumoral con aparición de zonas de hipoxia y acidosis, que pueden 
seleccionar células que han perdido la respuesta apoptótica a la hipoxia y por tanto amplian 
la clonación. Por otra parte, los factores angiogénicos puede modular la expresión de 
moléculas de adhesión celular y otros marcadores de la superficie del tumor del endotelio 
vascular. Por ejemplo, VEGF y el factor de necrosis tumoral-α (TNF-α) aumentan el 
número de moléculas de adhesión, mientras que el factor de crecimiento de fibroblastos 
(FGF) y el factor de crecimiento transformante β1 (TGF-β1) disminuye el número de 
moléculas de adhesión.  
La inflamación y la hipoxia contribuyen a la angiogénesis en las enfermedades no 
neoplásicas. En un adulto sano, las células endoteliales de los vasos sanguíneos se 
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encuentran en estado de reposo. En presencia de hipoxia o remodelación de la inflamación 
vascular ocurre la formación de nuevos vasos. Un aspecto de particular interés es que la 
angiogénesis en enfermedades no neoplásicas permiten la formación de nuevos vasos con 
estructura y función normal. La hipoxia es un estímulo muy importante de la angiogénesis 
así como de otros procesos biológicos que tratan de restaurar la oxigenación de los tejidos 
normales. El mecanismo básico es la activación de una proteína llamada HIF-1 (factor 
inducible de hipoxia 1). HIF-1 es una proteína heterodimérica formada por la unión de dos 
subunidades (HIF-1α y HIF-1β). Mientras HIF-1 β se expresa de modo constitutivo en todos 
los tejidos, HIF-1α se activa en condiciones de hipoxia. HIF-1 actúa en la región promotora 
de genes diferentes que tienen un elemento común de respuesta. Entre los genes activados 
por HIF-1 se encuentran genes relacionados con la angiogénesis como los que codifican 
para VEGF, óxido nítrico sintasa inducible (iNOS), factor del crecimiento derivado de las 
plaquetas (PDGF) y angiopoyetina 1 (ang1). Además, durante la inflamación no hay 
reclutamiento ni activación de células sanguíneas circulantes hacia el foco lesional. Muchas 
de estas células (por ejemplo, macrófagos, plaquetas, eosinófilos, mastocitos) liberan 
factores pro-angiogénicos. Además, los fagocitos son capaces de producir proteasas y  de 
estimular la liberación de factores angiogénicos de la matriz extracelular. 
Los cambios en la angiogénesis (por exceso o defecto) han sido observados en 
enfermedades múltiples donde la hipoxia o la inflamación desempeñan un papel importante. 
En particular, se han producido cambios en diversos tipos de enfermedades sistémicas, tanto 
autoinmunes (artritis reumatoide, lupus eritematoso, esclerosis múltiple), metabólicas 
(diabetes mellitus) o hematológicas (enfermedad de Castleman). Por otra parte, las 
modificaciones en la angiogénesis se han detectado en enfermedades localizadas que afectan 
al tracto gastrointestinal (enfermedad de Crohn), sistema nervioso central (esclerosis 
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múltiple, enfermedad de Alzheimer), respiratorio (enfisema pulmonar, fibrosis pulmonar 
idiopática) o riñón (glomerulonefritis). 
Los factores de crecimiento del endotelio vascular (VEGFs) son una familia de 
moléculas producidas por diferentes tipos celulares, entre los que se encuentran los 
eosinófilos. Desde su descripción inicial a principios de los años 80, los estudios acerca de 
la estructura y función de estas moléculas se han multiplicado de forma exponencial. Los 
VEGFs pertenecen a la superfamilia VEGF/PDGF (platelet-derived growth factor) y poseen 
como característica común tener ocho residuos de cisteína, dos de ellos relacionados con la 
formación de puentes intermoleculares y los otros seis implicados en la formación de 
puentes intramoleculares con formación de 3 dominios globulares. Se han descrito siete 
moléculas de la familia VEGF: VEGF-A, VEGF-B, VEGF-C, PlGF (placental growth 
factor), VEGF-E y VEGF-F. En mamíferos, únicamente los cinco primeros tienen 
importancia biológica, siendo VEGF-E una proteína vírica (virus Orf) y VEGF-F una 
proteína presente en el veneno de serpientes (víboras). Dentro de las 5 moléculas 
identificadas en humanos, la que reviste mayor importancia biológica es el VEGF-A, en 
muchas ocasiones denominado simplemente VEFG. El gen que codifica VEGF-A está 
formado por ocho exones. De forma característica, el ARN mensajero sufre un 
procesamiento alternativo, splicing, por el que las proteínas derivadas y englobadas con la 
denominación genérica de VEGF o VEGF-A son diferentes. La nomenclatura general de 
estas proteínas incluye, además de la denominación general (VEGF) el número de 
aminoácidos total (xxx) un sufijo (b) si el procesamiento alternativo afecta a la porción distal 
del exón 8. El número total de aminoácidos deriva principalmente de la inclusión o no de 
aminoácidos codificados total o parcialmente por los exones 6 y 7. Estos aspectos 
estructurales tienen una clara trascendencia biológica. Así, la inclusión o exclusión de los 
exones 6 y 7 modula las interacciones con proteoglicanos heparan sulfato (HSPGs) y 
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receptores tipo neuropilina. Por otro lado, el procesamiento proximal o distal del exón 8 
tiene consecuencias funcionales, ya que las isoformas VEGFxxx son proangiogénicas y las 
VEGFxxxb son antiangiogénicas. Las isoformas principales en el ser humano de VEGF-A 
son VEGF206, VEGF189, VEGF189b,VEGF165, VEGF165b, VEGF121 y VEGF121b. En las 
formas proangiogénicas, la isoforma que posee una mayor importancia biológica es 
VEGF165, seguida de VEGF121, VEFG189 y VEGF206. 
El VEGF-A ejerce su efecto biológico a través de la interacción con los receptores de 
superficie celular. Los receptores para VEGFs son de 5 tipos principales: VEGFR-1 
(vascular-endothelial growth factor-1), VEGFR-2 (vascular-endothelial growth factor-2), 
VEGFR-3 (vascular-endothelial growth factor-3), neuropilina-1 y neuropilina-2. Cada uno 
de los VEGFs presenta una selectividad específica por uno o varios de los receptores 
indicados. VEGF-A es capaz de unirse a todos ellos con excepción de VEGFR-3. VEGFR-1 
(también denominado fms-like tyrosine kinase; Flt-1) es una molécula constituida por 7 
dominios tipo Ig extracelulares, una región transmembrana y un dominio intracelular 
tirosina kinasa. Esta molécula se expresa en las células endoteliales, osteoblastos, células del 
sistema mononuclear fagocítico, células trofoblásticas placentarias, células mesangiales y 
algunas células madre hematopoyéticas. Aunque la afinidad del VEGFR-1 por VEGF-A es 
100 veces mayor que por VEGFR-2, su actividad tirosina kinasa es menor. En la 
embriogénesis, la expresión de este receptor está ligada a un efecto negativo en la 
angiogénesis. En periodos posteriores, la unión VEGF-A a VEGFR-1 parece que desempeña 
un papel importante en la generación de señales paracrinas en las células 
endoteliales.VEGFR-2 (también denominado KDR: kinase-insert domain receptor o flk-1: 
fms-like kinase) tiene una estructura muy similar a VEGF-1. Este receptor se expresa 
principalemente en las células endoteliales, aunque también se ha demostrado en neuronas, 
megacariocitos, osteoblastos y células hematopoyéticas. Las principales acciones de VEGF-
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A se ejercen por interacción con este receptor. Las neuropilinas 1 y 2 fueron identificadas 
como los receptores de una familia de moléculas conocidas como semaforinas/colapsinas, 
una familia de moléculas reguladoras del desarrollo del sistema nervioso. Ambas se 
expresan durante el desarrollo embrionario en tejido nervioso, cardiovascular y esquelético, 
mientras que en el adulto su expresión es muy amplia. El papel de las neuropilinas, 
principalmente de NP-1 es actuar como correceptor de VEGFR-2 aumentando su acción 
biológica.  
Muchos tipos celulares son capaces de desencadenar la síntesis y liberación de VEGF-
A en respuesta a estímulos muy diferentes: modificaciones metabólicas (hipoxia, 
hipoglucemia), hormonales (estrógenos), citocinas y otros factores de crecimiento, 
moléculas proinflamatorias y alteraciones genéticas. Uno de los mejor caracterizados es la 
hipoxia, que induce la estabilización y translocación al núcleo de dos factores HIF (hypoxic 
inducible factor) 1α e HIF2α . La unión con el factor nuclear HIF1β con los factores HIFa, 
al interaccionar con una región específica del gen del VEGF (HRE, hypoxia response 
element) induce la síntesis de esta molécula. Por otro lado, la hipoglucemia, tanto en 
estudios de laboratorio como clínicos da lugar a un aumento en la síntesis de VEGF: Los 
estrógenos también desempeñan un papel importante en la inducción de la producción de 
VEGF tanto en situaciones fisiológicas (ciclo menstrual, ovulación) como patológicas 
(cáncer de mama). Múltiples citocinas y factores de crecimiento inducen la producción de 
VEGF. Entre los mediadores inflamatorios relacionados con la producción de VEGF deben 
destacarse los radicales libres de oxígeno y el óxido nítrico. Finalmente, varios tipos de 
alteraciones genéticas, presentes en enfermedades hereditarias o tumorales se asocian a 
hiperproducción de VEGF. Las mejor caracterizadas se relacionan con mutaciones de p53, 
del gen que codifica la proteína de von Hippel-Lindau, de los genes supresores PTEN 
(phosphatase and tensin homologue deleted on chromosome 10).  
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La interacción entre VEGF-A y el receptor VEGFR-2 pone en marcha una serie de 
mecanismos de señalización iniciales que pueden ser resumidos en 5 fases: (i) unión del 
ligando al receptor, (ii) dimerización del receptor; (iii) activación de tirosina-cinasa; (iv) 
autofosforilación del receptor y (v) unión y activación de adaptadores a los lugares de 
autofosforilación. La vía de señalización del VEGF/ VEGFR-2 es diferente a la de otros 
factores de crecimiento. Básicamente tras la interacción entre VEGF-A y VRGFR-2 se 
activan 4 vías de transducción: (i) Activación de PI3K que transforma PIP2 en PIP3. Esta 
molécula actúa de dos formas en los efectos del VEGF: inhibiendo la apoptosis (por acción 
sobre BAD y caspasa 9) y estimulando la producción de óxido nítrico por acción sobre la 
isoenzima endotelial de la ONS. (ii) activación de CDC42 finalmente conduce a una 
reorganización de los filamentos de actina, (iii) Disminución de la adhesión de las células 
endoteliales empleando como molécula adaptadora Src y (iv) activación de la fosfolipasa C 
gamma que partiendo de PIP2 genera DAG e IP3. Las consecuencias de esta vía son de dos 
tipos: la generación de prostaglandinas y la activación de la proliferación de las células 
endoteliales. En resumen, los cuatro mecanismos por los que VEGF conduce a la 
angiogénesis son: (i) aumento de la supervivencia celular, (ii) incremento en la migración 
celular, (iii) estimulación de la proliferación celular y (iv) facilitación de la permeabilidad. 
FGF2 o factor de crecimiento de fibroblastos representa el mejor caracterizado de la 
familia de factores de crecimiento que unen heparina. FGF-2 es una molécula con efecto 
angiogénico potente in vivo e in vitro, que estimula el crecimiento de las células musculares 
lisas, la cicatrización de las heridas y la reparación de los tejidos. Además, el FGF-2 puede 
estimular la hematopoyesis y desempeñar un papel importante en la diferenciación y 
función del sistema nervioso, los ojos y el esqueleto. FGF-2 fue identificado como una 
proteína de 146 aminoácidos y más tarde como una forma proteolítica de 18 kDa. Contiene 
cuatro residuos de cisteína, sin bandas disulfuro intramolecular, un gran número de residuos 
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básicos y dos sitios que pueden estar fosforilados por proteínas quinasas A y C, 
respectivamente. La interacción de FGF-2 y la heparina protege a este factor contra el calor, 
la desnaturalización ácida y la fragmentación mediante proteasas. Mientras que la heparina 
es sólo sintetizada por las células cebadas del tejido conectivo, el sulfato de heparina se 
distribuye ampliamente en todos los órganos y tejidos de mamíferos, unida a proteínas 
básicas como la heparina sulfato proteoglicanos (HSPG). HSPGs son una clase funcional de 
diversas moléculas que se encuentran en la superficie celular y en la matriz extracelular, 
donde se ha demostrado que interactúan con FGF-2 y modulan su distribución y función.  
FGF-2 desempeña un papel clave en las diferentes etapas de la enfermedad en la 
mayoría de los órganos. Una de las actividades mejor caracterizadas es su capacidad para 
regular el crecimiento y la función de las células vasculares tales como las células 
endoteliales y del músculo liso. FGF-2 se ha implicado en el desarrollo y crecimiento de 
nuevos vasos sanguíneos (angiogénesis) y en la patogénesis de las enfermedades vasculares 
como la aterosclerosis. FGF-2 ha sido observado en el sistema nervioso de una variedad de 
especies. En el cerebro humano adulto, se ha encontrado en el sistema nervioso central y en 
las células de Purkinje del cerebelo, en los astrocitos, en poblaciones neuronales 
seleccionadas y ocasionalmente en las células de la microglia, encontrándose todas sus 
isoformas. En el pulmón, el FGF-2 se ha relacionado con la morfogénesis de la ramificación 
y el desarrollo de la fibrosis pulmonar. FGF-2, así como varios otros miembros de la familia 
FGF tales como FGF-4 y -8, estimulan el desarrollo de las extremidades. Sin embargo, es 
poco probable que FGF-2 sea el principal candidato para la formación de las extremidades 
ya que su patrón de expresión no se correlaciona con los eventos que ocurren durante la 
generación de estas. Los estudios de desarrollo indican que el FGF puede desempeñar un 
papel importante en el desarrollo muscular.  
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La proliferación, diferenciación y producción de TGF-β de osteoblastos son 
estimuladas por FGF-2. Además estimula la función de las células de Leydig. En el ojo, 
FGF-2 produce la inducción de la regeneración in vitro de la retina y protege a los 
fotorreceptores del daño de la luz. Por último, la proliferación y la diferenciación de los 
melanocitos normales humanos y las actividades de varios de los queratinocitos son 
dependientes de la producción de FGF-2. 
Los inhibidores de la angiogénesis son sustancias que inhiben el crecimiento de 
nuevos vasos sanguíneos. Pueden ser endógenos (proteínas o fragmentos de proteínas que se 
forman en el organismo) o exógenos (fármacos o componentes de la dieta). Uno de los 
principales inhibidores es la endostatina, proteína de 20 kDa, procedente de la división  del 
colágeno XVIII y que pertenece a la familia de las multiplexinas. La generación de 
endostatina desde el colágeno XVIII está catalizada por enzimas proteolíticos como 
catepsina L y metaloproteasas. Al igual que muchos otros inhibidores de la angiogénesis, 
endostatina tiene alta afinidad por la heparina, con un sitio que sirve de unión a la heparina. 
Este sitio participa en la inhibición de la angiogénesis inducida. También se une con baja 
afinidad a proteoglicanos sulfato de heparina, glipicano-1 y glipicano-4 y con alta afinidad a 
una molécula no identificada en las células endoteliales. Además se asocia con proteínas 
como integrinas, fibulinas, laminina-1 y tropomiosina. Por último, se ha observado que 
endostatina se introduce directamente en el citoplasma a través de las células endoteliales. 
Las funciones de la endostatina son diversas. La más conocida es la de ser un potente 
inhibidor de la angiogénesis endógena y por tanto supresor de tumores. Se ha observado en 
animales de experimentación que si se eliminaba la endostatina, los tumores crecían dos o 
tres veces más rápidos. Por el contrario, cuando la endostatina se sobreexpresaba, los 
tumores crecían tres veces más lentos. Algunos trabajos han demostrado que los ratones 
deficientes en endostatina mostraban aumento de la angiogénesis. Se han encontrado niveles 
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de endostatina elevados en ciertos tipos de cáncer, en líquido intratumoral, ascitis maligna y 
en enfermedades inflamatorias crónicas como la artritis reumatoide y la retinopatía 
diabética. 
Existe poca información sobre el papel de la angiogénesis y los factores angiogénicos 
en las helmintosis, tanto en los seres humanos como en modelos experimentales. Los 
factores angiogénicos producidos por el parásito o por el hospedador pueden estimular la 
neovascularización a través de varios mecanismos. Se ha demostrado que algunos genes de 
C. elegans (PVF-1) codifican un factor con capacidad de unión a los receptores de VEGF de 
los mamíferos, VEGFR-1 (FLT-l) y VEGFR-2 (KDR), que inducen angiogénesis. Respecto 
a los mecanismos utilizados por el hospedador, en primer lugar, tanto los factores de 
crecimiento del endotelio vascular (VEGF) como el factor de crecimiento de fibroblastos 
(FGF-2) inducen angiogénesis directamente, mediante la estimulación y proliferación de 
células endoteliales, y a través de la migración y diferenciación en los vasos. En segundo 
lugar, otros factores angiogénicos como la interleucina 1 (IL-1) promueven indirectamente 
la angiogénesis mediante la estimulación de las células inflamatorias para producir VEGF. 
En tercer lugar, la fragmentación de proteínas angiogénicas como la heparinasa libera 
péptidos que estimulan los componentes del sistema inmunitario del hospedador, el cual a 
su vez estimula la producción de factores angiogénicos como VEGF y FGF-2. Por último, 
algunos factores angiogénicos estimulan los mecanismos implicados en las lesiones 
definitivas. De hecho, datos experimentales sugieren que la hipoxia en relación con el 
VEGF puede estimular la proliferación de la síntesis de colágeno tipo1 en miofibroblastos 
activados. Esto ha demostrado que el VEGF y la angiopoyetina-1 (Ang-1) pueden funcionar 
como factores autocrinos y paracrinos dependientes de la hipoxia, capaz de estimular la 
migración y quimiotaxis de los miofibroblastos a través de la activación de señales Ras/Erk. 
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En la práctica, las principal información sobre angiogénesis y factores angiogénicos 
en las helmintosis se limita a las infecciones causadas por Schistosoma spp, filarias e 
infecciones por Taenia solium y Trichinella spp. 
La esquistosomosis está causada por la infección por diferentes especies del género 
Schistosoma. Con la excepción de la dermatitis cercariana y el síndrome de Katayama, la 
base patogénica de la esquistosomosis es la formación de granulomas alrededor de los 
huevos del parásito. Aunque la información de la literatura es escasa, observamos que en las 
etapas iniciales de la esquistosomosis existe estimulación de la angiogénesis. La presencia 
de angiogénesis en modelos experimentales de esquistosomiosis ha quedado claramente 
demostrada por técnicas histológicas e inmunohistoquímicas. En este contexto es interesante 
señalar varios aspectos: (i) La angiogénesis es un fenómeno temprano, así que en fases 
evolucionadas (como las que se encuentran en los seres humanos) es difícil observar. (ii) Un 
aspecto importante para que se genere angiogénesis es la necesidad de exposición repetida 
al parásito. (iii) Los factores genéticos desempeñan un papel esencial en la respuesta 
angiogénica frente al helminto. 
Los mecanismos por los que Schistosoma spp desencadena angiogénesis son de varios 
tipos y se han obtenido en estudios experimentales. Así, se han identificado moléculas 
reguladoras de angiogénesis derivadas de los huevos de S. mansoni como lisofosfatidilserina 
y prostanoides. También los huevos secretan factores adicionales que son capaces de 
estimular la proliferación y migración de células endoteliales y la fosforilación de p42/44 
MAPK. Este efecto no se limita a las células endoteliales, sino también estimula las células 
vasculares del músculo liso. Por otra parte, antígenos solubles de huevos de S mansoni 
(SEA) estimulan la proliferación y formación de nuevos vasos, disminuyendo la apoptosis y 
aumentando la expresión del gen para VEGF de las células endoteliales humanas de la vena 
umbilical (HUVECs). Estos hallazgos sugieren que los productos secretados por los huevos 
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de Schistosoma pueden promover la angiogénesis en los granulomas hepáticos por 
sobreexpresión de VEGF. Por otra parte, los huevos de Schistosoma que se adhieren al 
endotelio promueven indirectamente la angiogénesis a través de la hipoxia y de la respuesta 
inflamatoria, iniciada por TNF-α e ICAM-1. En etapas posteriores, se desarrolla fibrosis 
periportal por un mecanismo en el que participan linfocitos que producen moléculas 
profibroticas como TGF-β e IL-4. Por último, la infiltración de los huevos en el tejido 
circundante causa la migración de células inflamatorias hacia ese lugar. El sistema porta se 
interrumpe por completo alrededor de los granulomas y sólo se conserva muy cerca de la 
vena porta y de los conductos biliares. La proteolisis de la matriz extracelular mediante 
colágeno y metaloproteasas es un proceso anterior a la angiogénesis, pero necesario para 
permitir el desarrollo de una importante reacción inflamatoria. Aunque la proliferación de 
las células endoteliales de vasos maduros está en reposo, la presencia de múltiples células 
proliferativas en cada granuloma formado muestra la dinámica de la angiogénesis en la 
inflamación inducida por los esquistosomas. 
Solamente dos grupos de investigación han estudiado el papel de los factores 
angiogénicos en la esquistosomosis humana y sus resultados son difícilmente comparables. 
Por un lado, se evaluaron 90 pacientes con esquistosomosis producida por S. mansoni 
clasificados en cinco grupos de acuerdo a los estudios ecográficos: infección leve, intensa, 
intestinal, hepatoesplénica y con fibrosis periportal. Detectaron que los niveles de VEGF se 
elevaban significativamente en los pacientes con esquistosomosis en todos los grupos 
excepto los grupos con infección leve e intestinal. Además, el nivel de VEGF se 
correlacionaba con la progresión de la enfermedad desde infección ligera hasta el desarrollo 
de fibrosis periportal. Utilizando un diseño de estudio diferente, otro grupo de investigación 
midió los niveles séricos de VEGF en pacientes con esquistosomosis, con o sin hipertensión 
portal. Estos autores no encontraron diferencias significativas entre ambos grupos, aunque 
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los valores medios en el grupo con hipertensión portal eran más bajos, un hecho que 
coincide con los bajos niveles de VEGF detectados en pacientes con cirrosis por otras 
causas. 
Las filariosis son enfermedades relacionadas con la infección de varios géneros y 
especies de nematodos (Wuchereria bancrofti, Brugia malayi, Brugia timori, Onchocerca 
volvulus, Loa loa, Mansonella perstans, Mansonella ozzardi y Mansonella streptocerca). La 
alteración de la angiogénesis se ha descrito en dos tipos de filariosis: filariosis linfática y 
oncocercosis. Las manifestaciones de la filariosis linfática (específicamente las infecciones 
relacionadas con W. bancrofti) clinicamente se caracterizan por la presencia de linfedema, 
dilatación de los vasos linfáticos, extravasación de linfa y en algunos casos desarrollo de 
elefantiasis. Existen trabajos donde se estudia la relación entre factores angiogénicos (y 
específicamente de la familia del VEGF) y la patogénesis de la filariosis linfática. Así, en un 
estudio longitudinal en 63 pacientes polinesios que viven en un foco hiperendémico de 
W. bancrofti, se asoció la presencia de quiluria con un alto nivel del factor de crecimiento 
del endotelio vascular (VEGF). Sin embargo, los pacientes con elefantiasis presentaron 
elevados niveles de endotelina-1 (ET-1). Por otro lado se han relacionado factores genéticos 
con la clínica de la enfermedad y la determinación de factores angiogénicos. En una cohorte 
de pacientes con filariasis linfática procedentes de Ghana se examinaron tres polimorfismos 
de VEGF-A. Los autores encontraron que el genotipo C/C en 460 fue significativamente 
mayor en pacientes con hidrocele y en pacientes con niveles séricos elevados de VEGF. Por 
último, en una cohorte de pacientes infectados con W. bancrofti que tenían sobrexpresados 
los genotipos VEGF-C y sVEGFR-3 y que fueron tratados con doxiciclina (para la 
erradicación de la Wolbachia sp) tenían disminuidos VEGF-C y sVEGFR-3 y cuando 
llegaron a valores normales, presentaron mejoría clínica en sus síntomas. 
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La oncocercosis se caracteriza por dos tipos de manifestaciones clínicas: nódulos 
subcutáneos relacionados con filarias adultas y lesiones oculares relacionados con las 
microfilarias. Los nódulos que se originan en la infección por Onchocerca volvulus tienen 
diferentes patrones angiogénicos. Los nódulos pequeños tienen suministro adecuado de 
sangre con distribución difusa en toda la matriz de los nódulos, en estrecha asociación con 
los vermes adultos. Los nódulos mayores tienen una zona central más densa y no bien 
vascularizada y en las zonas más periféricas con vascularización intensa, alimentadas por 
vasos superficiales y en estrecho contacto con los vermes adultos. Al menos una proteína 
derivada de O. volvulus (homóloga a una secretada por Ancylostoma) puede contribuir a la 
alteración de la angiogénesis. 
La neurocisticercosis es una afección del sistema nervioso central (SNC) causada por 
la fase larvaria de Taenia solium. En esta infección se conoce la importancia de la respuesta 
granulomatosa. Una serie de ocho pacientes con neurocisticercosis sometidos a craneotomía 
para análisis histológico e inmunohistoquímico, mostró que el parásito al morir se rodea de 
un granuloma asociado a fibrosis, angiogénesis e infiltrado inflamatorio. Los tipos de 
células más abundantes fueron las células plasmáticas, linfocitos B y T (Th1), macrófagos y 
mastocitos. Además, se ha observado aumento de la angiogénesis en los modelos de 
neurocisticercosis en animales. 
La triquinelosis es una infección producida por distintas especies de Trichinella en el 
que existe una afectación de las células del músculo estriado. Las larvas del género 
Trichinella inducen la transformación de los miocitos en células nodrizas que se rodean de 
complejas redes de vasos sanguíneos. En ratones infectados experimentalmente por 
Trichinella se detectaron varias anomalías de los vasos. Así, los complejos vasculares se 
encontraron sólo alrededor de los miocitos infectados, caracterizándose por grandes vasos 
que se ramificaban en vasos pequeños formando redes. Esta redes son el resultado de la 
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angiogénesis de novo inducida durante la infección. En este contexto, los productos 
excretores/secretores derivados de larvas de T. spiralis y T. pseudospiralis están 
relacionados con cambios musculares (degenerativos, regenerativos) y angiogénesis. 
De la revisión anterior podemos afirmar que: (i) La angiogénesis es un proceso de 
formación de nuevos vasos importante no sólo en las enfermedades tumorales sino también 
en otras enfermedades, especificamente en helmintosis. (ii) Los estudios sobre el papel de la 
angiogénesis en helmintosis son escasos. (iii) No existe información bibliográfica acerca de 
la producción de factores angiogénicos por macrófagos ni del empleo de factores anti-
angiogénicos en helmintosis. (iv) Aunque se ha demostrado el papel del óxido nítrico en 
helmintosis y existe una relación documentada entre óxido nítrico y VEGF entre otros 
agentes angiogénicos, no se dispone de una información bibliográfica concreta acerca de la 
interacción de ambos mediadores inflamatorios en estas enfermedades parasitarias. 
Teniendo en cuenta estos datos los objetivos propuestos en esta Tesis Doctoral son:  
1.- Evaluar la expresión de factores angiogénicos (VEGF y FGF2) en macrófagos 
alveolares estimulados con diferentes antígenos procedentes de diversas fases del ciclo 
biológico de Trichinella spiralis, Trichinella pseudospiralis, Strongyloides venezuelensis y 
Schistosoma mansoni. 
2.- Estudiar la relación existente entre la expresión de factores angiogénicos y la 
producción de óxido nítrico, utilizando inhibidores específicos de la óxido nítrico sintasa 
inducible. 
3.- Emplear modelos in vitro de helmintosis para evaluar el efecto de factores anti-
angiogénicos (endostatina). 
4.- Utilizar modelos experimentales de infección de estrongioloidosis por 
S. venezuelensis y esquistosomosis por S. mansoni para valorar el efecto de factores anti-
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angiogénicos en el desarrollo de la infección, estudiando los mecanismos que puedan estar 
involucrados.  
5.- Analizar la producción de factores angiogénicos en sueros de pacientes con 
diagnóstico de helmintosis importadas. 
Tanto los materiales y métodos como los resultados y discusión de los experimentos 
realizados en esta Tesis Doctoral se han dividio en tres apartados que corresponden a los 
estudios realizados sobre angiogénesis y tres de la pricipales helmintosis: triquinelosis, 
estrongiloidosis y esquistosomosis. 
En el primer trabajo se estudia la expresión diferencial de factores angiogénicos en 
macrófagos estimulados con antígenos de especies encapsuladas y no encapsuladas de 
Trichinella. Este trabajo ha sido publicado en Experimental Parasitology 2009, 123: 347-
353. 
Los objetivos, metodología, resultados, discusión y conclusiones principales se 
exponen a continuación:  
Introducción: El estadio larvario de T. spiralis se introduce en la célula del músculo 
estriado formando la célula nodriza. Se detectó factor de crecimiento del endotelio vascular 
(VEGF) en en el área que rodea las células nodrizas. Sin embargo, no se dispone de datos 
sobre los antígenos implicados, el papel de otros factores angiogénicos o la relación de la 
angiogénesis con el óxido nítrico (ON).  
Metodología: Se usaron cultivos celulares de macrófagos alveolares para estudiar el 
efecto de diferentes antígenos de larva1 de T. spiralis (especie encapsulada) y T. 
pseudospiralis (especie no encapsulada) sobre la expresión de VEGF y factor básico de 
crecimiento de fibroblastos (FGF2). Además, se investiga la relación entre la producción de 
ON y los mediadores angiogénicos.  
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Resultados: Los resultados muestran que especies encapsuladas y no encapsuladas de 
Trichinella son diferentes en su capacidad de estimular la expresión de VEGF y FGF2 por 
los macrófagos alveolares. T. spiralis estimula la producción de factores angiogénicos 
mientras que T. pseudospiralis no es capaz de estimular estas células. Por último, no hay 
ninguna relación entre los factores angiogénicos y la producción de ON por el antígeno de 
T. spiralis. 
Discusión: Las especies encapsuladas se caracterizan por el depósito de colágeno y 
otros componentes de la matriz extracelular alrededor de las larvas de Trichinella. Un 
proceso clave asociado a la fibrogénesis es la angiogénesis. De hecho, los datos 
experimentales sugieren que la hipoxia en relación con el VEGF puede estimular la 
proliferación de la síntesis de colágeno tipo 1 en miofibroblastos. Nuestros resultados 
indican que los macrófagos son capaces de producir y liberar no sólo VEGF, sino también 
FGF2 en respuesta a los antígenos de las especies encapsuladas como T. spiralis en una 
manera dosis-dependiente. La expresión génica del VEGF se determinó mediante RT-PCR 
y expresión de la proteína medida por ELISA. Sin embargo, las especies no encapsuladas 
como T. pseudospiralis no fueron capaces de inducir la expresión de estos factores 
angiogénicos. La larva penetra en la célula muscular, crece en ella y destruye las 
miofibrillas. Las células satélite que rodean a la fibra muscular sufren cambios morfológicos 
transformándose en células nodrizas. Previamente se ha demostrado que las células nodriza 
son capaces de producir VEGF durante la infección por T. spiralis. En este trabajo se 
demuestra que las células inflamatorias que rodean a la fibra del músculo lesionado 
contribuyen a la producción de factores angiogénicos. Probablemente, ambos tipos de 
células están implicadas en el desarrollo de la cápsula de esta especie. Estudios previos 
realizados por nuestro grupo han demostrado que antígenos de especies encapsuladas y no 
encapsuladas de Trichinella fueron capaces de estimular la producción de óxido nítrico. 
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Como este mediador inflamatorio es un factor de inducción para la producción de VEGF, se 
evaluó si la inhibición de la óxido nítrico sintasa inducible, mediante el uso de inhibidores 
específicos como L-NAME y L-canavanina, modifican el efecto ejercido por los antígenos 
de Trichinella en la producción de factores angiogénicos. Este estudio demuestra que el 
efecto de los antígenos de T. spiralis no depende de óxido nítrico. En resumen, los antígenos 
de las especies encapsuladas de Trichinella estimulan directamente la producción de 
factores angiogénicos que pueden contribuir a la patogenia desarrollada en esta infección. 
En el segundo trabajo se estudia el papel de los factores angiogénicos en la infección 
aguda experimental desencadenada por Strongyloides venezuelensis. Este trabajo ha sido 
aceptado para publicación en Parasite Immunology el día 11 de Enero de 2010. 
Los objetivos, metodología, resultados, discusión y conclusiones principales se 
exponen a continuación:  
Introducción: Este estudio tiene como objetivo investigar el papel de los factores 
angiogénicos en la patogénesis de la estrongiloidosis experimental.  
Metodología: Dos enfoques complementarios fueron utilizados: En primer lugar, se 
trataron ratones CD1 con endostatina, un inhibidor de la angiogénesis, y posteriormente 
fueron infectados con Strongyloides venezuelensis. Además, se estudiaron los mecanismos 
implicados en este proceso. En segundo lugar, se investigó el efecto de los antígenos 
responsables de la estimulación de los factores angiogénicos (VEGF y FGF2) por 
macrófagos alveolares y los mecanismos implicados en su producción. Los macrófagos 
alveolares se obtuvieron por lavado broncoalveolar y se incubaron a diferentes 
concentraciones de antígenos somáticos y de excreción de secreción de S. venezuelensis. 
Además, los niveles de ARNm de VEGF y FGF2 fueron detectados por RT-PCR.  
Resultados: Los ratones tratados con endostatina mostraron disminución significativa 
de huevos por gramo de heces y del número de larvas obtenidas del pulmón. Los 
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mecanismos implicados en esta disminución pueden ser tanto directos, con disminución de 
los factores angiogénicos, como indirectos con aumento de eosinófilos. Además se ha 
comprobado que únicamente los antígenos somáticos de las larvas 3 estimulan VEGF y 
FGF2. Por último se ha observado la relación existente entre los factores de la angiogénesis 
y el óxido nítrico analizada mediante el uso de inhibidores de la óxido nítrico sintasa 
inducible. 
Discusión: La estrongiloidosis es una nematodosis de distribución cosmopolita que es 
especialmente relevante en individuos inmunocomprometidos, preferentemente en personas 
que reciben terapia con corticoides y en las regiones tropicales y subtropicales. Los 
mecanismos patogénicos en esta enfermedad son bastante desconocidos. Algunos autores 
han propuesto para el estudio de estos mecanismos modelos experimentales similares a 
S. stercoralis, utilizando especies de Strongyloides como S ratti y S. venezuelensis. El 
pulmón y las células que intervienen en su defensa, macrófagos alveolares, constituyen un 
primer elemento de estudio en la infección producida por este nematodo. Los trabajos 
realizados por nuestro grupo de investigación han puesto de manifiesto la producción de ON 
por macrófagos alveolares estimulados con antígenos larvarios de S. venezuelensis, 
demostrando la participación de este mediador inflamatorio en la estrongiloidosis 
experimental. Sin embargo, faltan estudios sobre el papel de otros mediadores inflamatorios 
y su posible relación con ON en la estrongiloidosis. La angiogénesis es un proceso complejo 
que conduce a la neovascularización generada a partir de los vasos sanguíneos preexistentes. 
Se asocia con la inflamación, la cicatrización de heridas, el crecimiento tumoral y la 
metástasis. La generación de nuevos vasos sanguíneos está regulada por las moléculas pro-
angiogénicas y antiangiogénicas. Los factores de crecimiento vascular endotelial (VEGF) y 
factores de crecimiento de fibroblastos (FGF) son los principales mediadores de la 
angiogénesis en el desarrollo y progresión de muchas enfermedades. Existen poco trabajos 
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donde se estudia la relación entre factores angiogénicos y helmintosis. Una correlación 
positiva se observó entre el VEGF en plasma y la aparición de hidrocele en personas 
infectadas con W. bancrofti. Además, se encontró VEGF como factor protector en la malaria 
cerebral. En este trabajo nos planteamos evaluar el papel de factores angiogénicos en la 
estrongiloidosis experimental. Para ello  estudiamos: (i) La modulación de la infección 
utilizando inhibidores específicos de la angiogénesis como la endostatina. (ii) La inducción 
de VEGF y FGF2 en macrófagos alveolares estimulados con antígenos derivados de 
distintas fases del ciclo biológico de S. venezuelensis y (iii) la relación entre estos factores y 
la producción de ON. La endostatina es una molécula de 20 kDa que pertenece al fragmento 
carbóxilo terminal del colágeno XVIII que cuando se añade de forma exógena inhibe la 
angiogénesis. En este estudio se demuestra que los factores angiogénicos tienen un papel 
relevante en la primoinfección por S. venezuelensis. El uso de endostatina disminuye tanto 
el número de larvas en el pulmón como la producción de huevos en heces. ¿Esto es debido a 
efectos directos sobre el parásito o indirectos vía hospedador? Para responder a esta 
cuestión, realizamos estudios in vitro sobre efecto de la endostatina sobre la supervivencia o 
mortalidad de los parásitos. Los resultados demuestran que la endostatina no tienen efecto 
directo sobre el parásito. El efecto indirecto sobre el hospedador puede ser atribuido a dos 
mecanismos complementarios. En primer lugar disminuyendo directamente la producción 
de factores angiogénicos, dato que se observa en nuestro estudio mediante la reducción de la 
expresión de VEGF y FGF2 en el pulmón y el intestino. En segundo lugar, algunos autores 
han observado que los eosinófilos tienen la posibilidad de participar en la angiogénesis 
mediante la inducción de la producción de VEGF. Por otra parte, el VEGF se ha asociado 
con la alteración de la barrera hematoencefálica en pacientes con meningitis eosinofílica 
causada por Angyostrongylus cantonensis. Nuestros datos indican que los ratones infectados 
con S. venezuelensis y tratados con endostatina tienen menor número de eosinófilos. Los 
macrófagos son conocidos por producir varios factores angiogénicos, incluyendo el potente 
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factor de crecimiento del endotelio vascular (VEGF), factor de crecimiento de la placenta 
(PlGF), factor básico de crecimiento de fibroblastos (FGF2), factor de crecimiento 
transformante β (TGF-β), interleucina-8 (IL-8) y una gran cantidad de citocinas pro-
inflamatorias, como la interleucina-1β (IL-1β), la interleucina-6 (IL-6), el factor de necrosis 
tumoral alfa (TNF-α) y el factor estimulante de colonias de granulocitos y monocitos (GM-
CSF). Los estudios realizados por nuestro grupo han demostrado la producción de VEGF y 
FGF2 en macrófagos alveolares estimulados con antígenos larvarios de T. spiralis. En este 
trabajo nos hemos propuesto estudiar los antígenos de S. venezuelensis responsables de la 
inducción de factores angiogénicos. Para ello utilizamos antígenos somáticos y excretores 
secretores de larva y hembras de S. venezuelensis. Solamente el antígeno somático de larva 
III de S. venezuelensis estimula la producción de VEGF y FGF2 en macrófagos alveolares y 
estos factores están asociados con la infección originada por este nematodo. Futuros 
estudios mediante análisis proteómico irán encaminados a dilucidar las moléculas 
procedentes del antígenos somático larvario responsables de este efecto. Estas podrán servir 
como dianas terapéuticas para diseñar vacunas frente a Strongyloides. El óxido nírico 
producido por los macrófagos activados y las células endoteliales es una molécula de 
señalización intracelular e intercelular generados a partir de L-arginina, que podría estar 
relacionado con las etapas de la angiogénesis. En este trabajo estudiamos la posible relación 
entre estos mediadores tras la estimulación macrofágica de los antígenos somáticos larvarios 
de S. venezuelensis. Utilizamos inhibidores de la iNOS como L-NAME y L-canavanina y 
hemos podido comprobar la asociación entre la producción de ON y la producción de 
factores angiogénicos, ya que estos inhibidores son también capaces de inhibir la expresión 
de los factores angiogénicos. Esta relación no se observó en la inducción de VEGF y FGF2 
por antígenos larvarios de T. spiralis.  
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En el tercer trabajo se estudia la expresión de los factores de angiogénicos en la 
esquistosomosis humana y experimental. Este trabajo ha sido enviado para publicación a 
Plos Neglected Tropical Diseases el día 18 de Enero de 2010. 
Los objetivos, metodología, resultados, discusión y conclusiones principales se 
exponen a continuación:  
Introducción: La angiogénesis, el proceso de formación de nuevos vasos sanguíneos, 
tiene un papel importante en diversos procesos, incluyendo el cáncer y la inflamación. La 
esquistosomosis es una helmintosis que afecta a más de 200 millones de personas en el 
mundo. Los trabajos anteriores han demostrado que los antígenos solubles de Schistosoma 
mansoni inducen la expresión del factor de crecimiento del endotelio vascular (VEGF) en 
células endoteliales humanas. Los objetivos del estudio son: (i) Estudiar la presencia de 
VEGF en suero de pacientes diagnosticados de esquistosomosis y de otras helmintosis. (ii) 
Evaluar el efecto de endostatina en modelo experimental murino infectado con S. mansoni. 
(iii) Detectar VEGF y factor de crecimiento de fibroblastos (FGF2) en macrófagos 
alveolares estimulados con antígenos de cercaria y adultos de S. mansoni.  
Metodología: Se han utilizado sueros de pacientes sanos y con diagnóstico 
parasitológico de esquistosomosis y otras helmintosis, para detectar VEGF mediante un 
técnica de ELISA comercial. Además se han empleado ratones CD1 divididos en tres 
grupos: (i) Sanos. (ii) Ratones infectados con 150 cercarias de S. mansoni. (iii) Ratones 
infectados y tratados con endostatina. Las magnitudes analizadas fueron: datos 
parasitológicos, hematológicos, detección de IgG, IgG1 e IgG2a específicas mediante 
ELISA y expresión de VEGF y FGF2 en hígado e intestino mediante RT-PCR. Por último 
se ha evaluado en macrófagos alveolares la expresión de VEGF y FGF2 estimulados con 
diferentes antígenos de S. mansoni mediante RT-PCR. 
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Resultados: En primer lugar, los pacientes diagnosticados con esquistosomosis 
mostraron diferencias significativas en la detección de VEGF respecto a los demás grupos 
estudiados. Sin embargo, no hubo diferencias entre los pacientes infectados por S. mansoni 
y S. haematobium. En segundo lugar, los ratones infectados y tratados con endostatina 
mostraron diferencias significativas en la disminución del número de huevos presentes en 
hígado y en la detección de anticuerpos IgG2a específicos. Por último, solo se observó 
expresión de VEGF y FGF2 en macrófagos alveolares estimulados con 50µg/ml de antígeno 
de cercaria de S. mansoni. 
Discusión: Las principales helmintosis que afectan a la población humana son 
geohelmintosis, esquistosomosis y filariosis. También son estas helmintosis las detectadas 
en pacientes inmigrantes asintomáticos con eosinofilia absoluta o relativa. En este trabajo 
nosotros evaluamos VEGF en sueros de pacientes diagnósticados con una helmintosis. Para 
ello seleccionamos inmigrantes subsaharianos con eosinofilia donde la realización de un 
estudio detallado mostraba la presencia de un solo helminto, no de coinfecciones. 
Encontramos que los pacientes diagnosticados de esquistosomosis tenían niveles 
significativos de VEGF en suero respeto al grupo de pacientes sanos. Estos resultados son 
similares a los observados por otros autores en infecciones por S. mansoni. También 
pudimos comprobar que no había diferencias significativas entre los valores de VEGF 
encontrados en esquistosomosis por S. mansoni y por S. haematobium. La angiogénesis 
juega un papel fundamental en muchos procesos fisiológicos y patológicos, incluyendo el 
desarrollo de la fibrosis hepática. En la cirrosis, se reducen los niveles de VEGF en suero. 
Sin embargo, se detectaron altos niveles de VEGF en el suero de pacientes con 
esquistosomosis, aunque otros autores encontarron valores diferentes de VEGF en las 
distintas fases clínicas de la esquistosomosis. Además hemos comprobado que los 
eosinófilos no son las únicas células implicadas en la expresión de VEGF en humanos ya 
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que no hay asociación entre el número de eosinófilos y los valores de VEGF. En la segunda 
parte de nuestro trabajo, nosotros estudiamos en un modelo experimental de S. mansoni, los 
efectos que se producían tras la inhibición por factores anti-angiogénicos. Para ello 
utilizamos endostatina como inhibidor específico de la angiogénesis. Ratones infectados con 
S. mansoni y tratados con endostatina no presentaban reducción significativa de vermes 
adultos. Sin embargo, había reducciones significativas en el número de huevos en hígado, 
así como en el número de granulomas hepáticos. Esto indica que la inhibición de la 
angiogénesis induce una disminución de las lesiones hepáticas desencadenantes de la 
formación del granuloma y por tanto de la fibrosis hepática subsiguiente. A continuación 
estudiamos los posibles mecanismos implicados en la reducción de la lesión. En primer 
lugar analizamos datos de recuento de serie roja, blanca y plaquetas. No observamos 
diferencias significativas en ninguno de los datos analizados, específicamente en la 
reducción del número de eosinófilos. Estos resultados obtenidos en el modelo experimental 
concuerdan con lo observado en sueros humanos. Este dato es opuesto al hallado por 
nuestro grupo cuando analizamos la relación angiogénesis y estrongiloidosis. En segundo 
lugar pudimos demostrar la disminución de la expresión de VEGF y FGF2 en hígado. Este 
dato demuestra la inhibición efectiva realizada por endostatina. En tercer lugar analizamos 
la respuesta inmunitaria producida entre los grupos de estudio. Encontramos disminución 
significativa en la detección de IgG2a específicas. Esta reducción está relacionada con la 
disminución de respuestas Th1 efectoras en los animales tratados con endostatina, en los 
cuales existe reducción en el número de huevos en hígado y de granulomas observados. 
Estos resultados coinciden con las observaciones de otros autores en que la esquistosomosis 
grave se asocia con elevación persistente de citocinas pro-inflamatorias tipo Th1, mientras 
que la afección más leve está presente cuando aumentan las citocinas tipo Th2. Por otra 
parte, el cambio hacia la producción de citocinas tipo Th1 producidas por una población 
estable de células CD4+ se correlaciona con la exacerbación grave de la inmunopatología de 
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la esquistosomosis. El último objetivo de nuestro estudio fue identificar los antígenos de 
S. mansoni que participan en la expresión de VEGF y FGF2 producido por los macrófagos 
alveolares. Usamos antígenos de cercarias y de vermes adultos de S. mansoni. Nuestros 
resultados han mostrado que los antígenos de cercaria eran capaces de estimular la 
producción de factores angiogénicos en macrófagos alveolares. Estos resultados y los datos 
obtenidos por otros autores muestran el papel de la angiogénesis en la esquistosomosis y su 
participación en la reacción granulomatosa asociada a la lesión. En resumen, este estudio 
pone de manifiesto el papel de la angiogénesis en la patogenia de la esquistosomosis debido 
a tres aspectos: (i) La detección de VEGF en pacientes con diagnóstico de esquistosomosis. 
(ii) La reducción de huevos y la formación de granulomas en el hígado de ratones tratados 
con endostatina con predominio de respuestas tipo Th1. (iii) El aumento de expresión de 
VEGF y FGF2 tras la estimulación de macrófagos alveolares por antígenos de cercarias de 
S. mansoni. 
Finalmente las conclusiones de esta tesis doctoral son son:  
1.- Los antígenos de la especie encapsulada Trichinella spiralis son capaces de 
estimular de forma dosis-dependiente los factores angiogénicos como VEGF y FGF2 por 
macrófagos alveolares de rata. 
2.- La angiogénesis desempeña un papel relevante en la primoinfección por 
Strongyloides venezuelensis, ya que su inhibición mediante el empleo de endostatina 
produce disminución de las magnitudes de infección. 
3.- La endostatina reduce la infección de Strongyloides venezuelensis no por acción 
directa sobre el parásito sino a través de efectos indirectos como la disminución de la 
producción de factores angiogénicos por el hospedador o la reducción de la respuesta 
eosinofílica.  
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4.- Los antígenos somáticos larvarios de Strongyloides venezuelensis son los 
responsables de la inducción de factores angiogénicos y su modulación está relacionada con 
la generación de óxido nítrico. 
5.- En pacientes con esquistosomosis existe un aumento en los niveles séricos de 
VEGF con diferencias significativas con respecto a otras helmintosis. 
6.- La inhibición de la angiogénesis mediante endostatina en la esquistosomosis 
experimental murina induce una disminución en el número de huevos en hígado, así como 
en la presencia de granulomas y de fibrosis hepática. 
7.- Los antígenos de cercarias de S. mansoni inducen la expresión de factores 
angiogénicos en macrófagos alveolares de rata. 
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6 Methodological appendix 
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6.1 Collection of rat alveolar macrophages samples for measurement of nitric oxide. 
Alveolar macrophages from male Wistar rat were obtained by bronchoalveolar lavage 
Espinoza et al., (2002) and Nurkiewicz et al., (2004). Lungs were lavaged with aliquots of 5 
ml of sterile PBS with sterile cannula for collection of BAL fluid as order that come below. 
Male Wistar rats are used in all experiments and alveolar macrophages were obtained by 
bronchoalveolar lavage technique (BAL). 
Materials: 
- Male Wistar rat weighting 250-300 g. 
- Sodium pentobarbital (≥100 mg/kg, i.p.). 
- Teflon catheter (VYCON Code 123.06). 
- Phosphate-Buffered Saline (PBS lx sterile pH 7.4) 
- Ethanol (141086, Panreac). 
- Thoma Pipette. 
- Microspirator (258 00, Brand). 
- Liquid of Turk (251390, Panreac). 
- Neubauer. 
Procedure: 
- Rats were euthanized with an intraperitoneal injection (ip) of sodium pentobarbital 
≥100 mg /kg body weight. 
- A tracheal cannula (teflon catheter) was inserted. 
- BAL was performed through the cannula using ice-cold PBS (each time, to inject 5 ml 
of PBS sterile with pH 7.4 through the cannula and collection BAL with a syringe 5 ml) 
and repeat 10 to 15 times, and collect BAL in a 50 ml tube. 
- Centrifuge BAL at 500 g for 10 min at 4ºC and remove the supernatant. 
- Macrophage cells resuspended cells in 1 ml of Dulbecco’s medium. 
- The isolation of acellular BAL fluid and BAL cells were counted as described Porter et 
al., 2004). 
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6.2 Rat alveolar macrophages cultures  
Rat alveolar macrophages were exposed to different concentrations of extracts of 
S. venezuelensis, using the basal cells (macrophages) as a negative control and macrophages 
stimulated with LPS as a positive control. The procedure is based on the technique 
described by Evans et al. (2002a) and Andrade et al. (2005a). 
Materials:  
- Dulbecco’s modified Eagle’s medium (DMEM, D-0819 Sigma). 
- Fetal bovine serum (12003C, Sigma). 
- Glutamine (G-5792, Sigma). 
- Complete medium (10% fetal bovine serum, 2mM of glutamine, 100U/100µg/ml 
penicillin-streptomycin and 44 ml of DMEM). 
- Peniciline y estreptomicine (P-4333, Sigma-Aldrich, Inc., San Luis, EE.UU.). 
- Culture Plates (Costar, Cambridge, MA). 
- Lipopolysaccharide (LPS) (L-2880, Sigma) 
- Polymixin B (PMB P-4932, Sigma) 
- L-NAME: Nω-nitro-L-arginin methyl ester hydrochloride (N-5751, Sigma) 
- L-canavanine (C-9758, Sigma) 
- Trypsin (T9935, Sigma) 
- Incubator of CO2 (Galaxy St, BIOTECH) 
Procedure: 
- Macrophages (1×106/well) were washed with DMEM two times and then were placed 
on culture plates. 
- Incubate 2h at 37ºC in 5% CO2 to adhere cells on the plastic bottom of the culture 
plates. 
- Remove non-adhering cells by gentle washing with complete medium and discard it and 
add 1 ml of fresh complete medium for further cell culture. 
- Incubated adherent alveolar macrophages alone (as a negative control, Ø), with 
lipopolysaccharide (LPS) as a positive control with several concentrations, ranging from 
0.1 to 50 µg protein/ml, with different antigens. 
- Incubate for 18h at 37ºC in 5% CO2, then culture supernatants collected and centrifuged 
at 500 g for 10 min. 
- Collect supernatants after 18h, centrifuge at 500 g for 10 min and store at -80ºC as an 
archival material. 
- Recovered macrophages and stored at-80ºC. 
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6.3 Determination of viability of rat alveolar macrophages 
The cell viability was assessed by mitochondrial reduction of MTT after removing the 
supernatant according to Kiemer and Vollmar (1997). Cell viability, should be higher than 
87.5% in all cases. 
Materials: 
- Spectrophotometer (Easy Reader EAR 400FT). 
- MTT: (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide; M2003, 
Sigma). 
- Dimethyl sulfoxide (DMSO, 07-4872, Sigma) 
- 96wells Plates 
Procedure:  
- Add 200 µl of MTT (0.5 mg/ml) in each well and incubate alveolar macrophages for 1 
hr at 37ºC 
- Remove MTT completely from all plate and add 200 µl of DMSO or 50%ethyl alcohol 
with 50%DMSO 
- Determine optical density immediately at 550nm in a Easy reader EAR 400 FT 
photometer. 
- Following the measure viability of cells, alveolar macrophages were collected and store 
them at -80ºC. 
6.4 Griess assay for measure of nitrites. 
To measure nitric oxide in the cell culture supernatant was used Griess technique that is 
based on the property have nitrites react with primary aromatic amino acid medium, 
resulting diazonium compounds that give color pink (Green et al., 1982; Campisi et al., 
2002). Supernatant of macrophage culture are used for nitrite determination according to 
Andrade et al. (2007). 
Materials:  
- Solution A: 1% sulfanilamide, 0.12M (S-9251, Sigma) in H3PO4 0.36 M 
- Solution B: dihidrocloruro of N-(1-naftil) etilendiamine 7.7mM (N-5889, Sigma) in 
H3PO4 0.36 M 
- Stock solution: 1 M of NaNO2 (S-2252-500G, Sigma). 
- Spectrophotometer (Easy Reader EAR 400FT) 
Procedure: 
- Make different dilution of medium that we want to determine nitrites from 1 µM to 
100 µM. 
- Prepare the Griess reagent, solution A and solution B, mix them and prepare with the 
equal portion immediately before their utilization. 
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- Add 100 µl to each well of blank (only complete medium), patron and sample triplicate 
in 96 wells plaque.  
- Add 50 µl of reagent of Griess for each well; incubate 15 min in bench top (20-30 ºC). 
- Measured the absorbance of the azochromophore at 550 nm. 
6.5 Extraction of RNA from rat alveolar macrophages 
For the RNA extraction from macrophages was used the commercial kit RNeasy Mini 
Kit (Qiagen). This kit is used for purification of total RNA from animal cells and animal 
tissue and for cleanup of RNA from crude RNA prep and enzymatic reactions. 
Materials:  
- RNeasy Mini Kit (Code, Qiagen) 
- Qiashreder (Code, Qiagen) 
- RNase-Free DNase Set (Code, Qiagen) 
Procedure: 
- Determine the number of cells (macrophages, between 106-107cells) and centrifuge them 
for 5 min at 300 × g. Then carefully remove all supernatant by aspiration and proceed to 
step 2. 
- Add appropriate of Buffer RLT (350-600 µl) for disruption the cells. Vortex or pipet 
them to mix and go to the third step. 
- Homogenize the lysate for 2 min centrifuge at full speed using Qiashreder spin column. 
- Add 1 volume of 70% ethanol (the same volume of lysate) to homogenized lysate and 
mix well by pipeting. 
- Transfer 700 µl of the sample to an RNeasy spin column placed in a 2 ml collection 
tube. Then gently closed the lid and centrifuge them for 15 s at 8000g and after that 
discard the flow-through. 
- Add 350 µl of RW1 to the RNeasy column, closed the lid gently and centrifuge 15 
seconds at 8000 g (for washing the column membrane). Throw away the flow-through. 
- Add 80 µl of DNase l incubation mix (add 10 µl DNase enzymes to 70 µl RDD buffer 
and mix them gently) to the spin column membrane and place on the bench top for 15 
min at 20-30ºC. 
- Add 350 µl RW1 to the spin column, close the lid gently and centrifuge for 15 seconds 
at 8000g. Then discard the flow-through. 
- Add 500 µl of RPE buffer to the column, close the lid gently and centrifuge at 8000g for 
15 seconds (For washing the column membrane), then throw away the flow-through. 
- Add again 500 µl of RPE buffer to the column, close the lid slowly and centrifuge them 
for 2 min at 8000g to wash the column membrane. 
- Place the spin column in a new 2 ml collection tube and discard the old collection tube 
with the flow-through. Close the lid gently, and centrifuge at full speed for 1 min. 
- Finally, put the spin column in a new 1.5 collection tube and add 30-50 µl RNase-Free 
water directly to the column membrane. Close the lid slowly and centrifuge at 1 min at 
8000 x g to elute the RNA. 
- Store RNA at-80ºC. 
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6.6 RNA extraction from experimental animal tissue  
It is essential to use the correct amount of stating material in order to obtain optimal 
RNA yield and purity from liver, intestine and lung. A maximum amount of 30 mg fresh or 
frozen tissue or 15-20 mg RNA later stabilized tissue. 
Materials:  
- RNeasy Mini Kit (Qiagen) 
- Qiashreder (Qiagen) 
- RNase-Free DNase Set (Qiagen) 
- Mortar and pestle 
Procedure: 
- Weight 10-30 mg of tissue and cut it into slices less than 0.5 cm thick as quickly as 
possible. Then the tissue pieces completely submerge in the RNAlater (Stabilization 
reagent). For archival storage at -20ºC, first incubate the tissue overnight in the 
RNAlater at 2-8ºC. Then remove the tissue from the reagent, and transfer it to -20ºC for 
storage. 
- Place the weighed (fresh, frozen, or RNAlater stabilized) tissue in liquid nitrogen, and 
grind thoroughly with a mortar and pestle. Decant tissue powder and liquid nitrogen into 
an RNase-Free, liquid-nitrogen-cooled, 2 ml microcentrifuge tube. Allow the nitrogen 
liquid to evaporate but don’t allow thawing the tissue.  
- Add the appropriate volume of RLT buffer, and pipet the lysate directly into a 
QIAshreder spin column placed into a 2 ml collection tube and centrifuge for 2 min at 
full speed. 
- Centrifuge the lysate for 3 min at full speed and then carefully removed the supernatant 
by pipeting, and transfer it to a new microcentrifuge tube. We use only this supernatant 
(lysate) in subsequent steps. 
- Add 1 volume of 70% ethanol (the same volume of lysate) to homogenized lysate and 
mix immediately by pipeting (don’t centrifuge it). 
- Transfer 700 µl of the sample to an RNeasy spin column placed in a 2 ml collection 
tube. Then gently closed the lid and centrifuge them for 15 s at 8000g and after that 
discard the flow-through. 
- Add 350 µl of RW1 to the RNeasy column, closed the lid gently and centrifuge 15 
seconds at 8000g (for washing the column membrane). Throw away the flow-through. 
- Add 80 µl of DNase l incubation mix (add 10 µl DNase enzymes to 70 µl RDD buffer 
and mix them gently) to the spin column membrane and place on the bench top for 15 
min at 20-30ºC. 
- Add 350 µl RW1 to the spin column, close the lid gently and centrifuge for 15 seconds 
at 8000g. Then discard the flow-through. 
- Add 500 µl of RPE buffer to the column, close the lid gently and centrifuge at 8000 g 
for 15 seconds (For washing the column membrane), then throw away the flow-through. 
- Add again 500 µl of RPE buffer to the column, close the lid slowly and centrifuge them 
for 2 min at 8000 g to wash the column membrane 
- Place the RNeasy spin column in a new 2 ml collection tube and discard the old 
collection tube with the flow-through. Close the lid gently, and centrifuge at full speed 
for 1 min. 
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- Then, place the RNeasy spin column in a new 1.5 collection tube. Add 30-50 µl RNase-
Free water (Depend the RNA yield) directly to the column membrane. Close the lid 
slowly and centrifuge for 1 min at 8000g to elute the RNA. 
- If the expected RNA yield is 30 µg, repeat the step 13 using another 30-50µl RNase free 
water, or using elute from step 13 (If we want high RNA concentration). 
- Store RNA at-80ºC immediately and it is essential that working with RNA fast because 
it’s very instable and degrade rapidly. 
6.7 RT-PCR for detection of VEGF and FGF2 in alveolar macrophages  
It was performed with RT-PCR kit (11483188001, Roche) by RNA extracted from rat 
alveolar macrophages. It is the first complementary DNA strand in two steps; synthesis at 
42ºC and denaturation at 95ºC (Andrade et al., 2005). 
Materials: 
- Sterile vials of 0.5 ml. 
- Thermal cycler (Perkin Elmer Instrument, Norwalk, USA). 
- Oligonucleotides OligodT (27-7858, Pharmacia Biotech). 
- Mastermix (cDNA). 
- Nuclease-free water (DEPC). 
Table 5.1: Reagent and amount and final concentration per sample for RT-PCR. 
Reagent Volume.1 sample Final conc. 1 sample 
10× Reaction Buffer 2.0 µl 1× 
25mM MgCl2 4.0 µl 5mM 
Deoxynucleotide Mix 2.0 µl 1mM 
Oligo-p (dT)15 2.0 µl 0.04 A260 units (1.6µg) 
RNase Inhibitor 1.0 µl 50 units 
AMW Reverse Transcriptase 0.8 µl ≥20 units 
Sterile water variable - 
RNA sample variable - 
Total 20µl  
Procedure: 
- The amount of RNA sample add to sample reactions (The amount of RNA that added to 
sample reaction is depends on the nature of the RNA used and on the intended 
application; normally, ≤1µg of total RNA, 50-100 ng of poly [A] + RNA, or 6 fg-1µg of 
a single, purified RNA species [e.g., the control Neo pa RNA] is required according 
Table 5.1. 
- Briefly vortex and centrifuge the mixture to collect the sample at the bottom of the 
microfuge tube.- Incubate the reaction at +25ºC for 10min; during the first 
incubation, primer anneals to the RNA template. 
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- Then incubate the reaction at +42ºC for 1hr; during the second incubation, The RNA is 
subsequently reverse transcribed, resulting in cDNA synthesis. 
- The AMW Reverse Transcriptase denatured by Incubation the reaction at 99ºC for 5 
minutes.  
- Cool the reaction at 4ºC for 5 minutes. 
- At this point, the reaction tube maybe stored at +2 to 8ºC for 1-2h or at −15to−25ºC for 
longer periods. 
6.8 Chain reaction polymerase (PCR). 
VEGF is determined in rat alveolar macrophages after cultivation and determination of 
viability. Total RNA was extracted from macrophages following the instructions of the 
commercial kit RNeasy Mini Kit (Qiagen GmbH, Hilden Germany).Then a total 1 µg RNA 
was used as template for the first-strand DNA synthesis (Roche 1483188). The VEGF insert 
amplification was performed with primers described by Yang et al. (2004) and FGF-2 insert 
amplification was performed with primers described by Jyo-Oshiro et al. (1999). Primer 
sequence for VEGF was: sense, 5´-CTGCTCTCTTGGGTGCACTGG-3´ and anti-sense, 5´-
CACCGCCTTGGCTTGTCACAT-3´. Primer sequence for FGF2 was: sense, 
5´GCCGGCAGCATCACTTCGCT-3´ and anti-sense, 5´CTGTCCAGGCCCCGTTTTGG-
3´. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as an internal control 
and GAPDH sense, 5´-GGTCGGTGTGAACGGATTTG-3´ and GAPDH anti-sense, 5´-
GTGAGCCCCAGCCTTCTCCAT -3´. To reveal the reaction, the PCR product was 
separated in an agarose gel and ethidium bromide. 
Materials: 
- 10X Buffer (Promega M1906). 
- MgCl2 (25mM). 
- Deoxynucleotide mix 1 mM (Boehringer Mannheim, 1 093 088). 
- Taq DNA polymerase (Promega, M1665). 
- Water DEPC. 
- Primers: VEGF 20 mM, FGF-2 20mM and GAPDH 20 mM. 
- Thermal cycler. 
- Template cDNA. 
Procedure: 
- For each reaction to a container with 20 µl in each eppendorf 2 µl of buffer, 3 mM of 
MgCl2 50mM, 2mM of deoxynucleotide mix1 mM and 0.125 µl of Taq DNA 
polymerase. 
- Add to each reaction 1mM of each primer in case of VEGF and GAPDH and 0.5 mM in 
case of FGF-2. 
- Add 1µg of blank sample and complete up to final volume 20 µl of sterile water and 
mixed well. 
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- Incubate 94 ºC for 5min, 35 cycles of 94ºC for 1min, 55 ºC for 1 min, 72 ºC for 1 min. 
and a single cycle at 72ºC for 7 min in case of VEGF and GAPDH. 
- Incubate 94 ºC for 2min, 50 cycles of 94 ºC for 30 s, 60 ºC for 30 s, 72ºC for 1 min and 
a single cycle at 72 ºC for 5 min. in case of FGF-2. 
- At the end of cycles programmed at 4°C. 
6.9 DNA electrophoresis in agarose gel with ethidium bromide 
To view the products obtained by PCR is necessary to observe in an agarose gel with 
ethidium bromide, confirming its size and compare them with a marker. Ethidium bromide 
is mutagenic and carcinogenic and therefore must avoid inhaling the vapors and must be 
handled with gloves. 
Materials: 
- TAE buffer solution. 
- Agarose (A9539, Sigma). 
- Microwave. 
- Ethidium bromide (161-0433, Bio-Rad). 
- Loading buffer. 
- Molecular marker (1Kb Plus DNA Ladder). 
- Transilluminator UV, BioDoc-It System. 
- Template cDNA 
Procedure: 
- Take 60 ml of TAE buffer solution and add 0.6 g agarose and heated in a microwave for 
two minutes for preparing the gel. 
- Cool the gel up to 50°C and add 0.5 µl ethidium bromide and shake it until 
dissolved. 
- Pour into the tray and place the molds to form the wells.- Put in a vial 10 µL of 
the sample and add 4 µl loading buffer. 
- In the first well pour 2.5 µl of molecular marker (1Kb Plus DNA Ladder) and 2.5 
loading buffer. 
- Place in each well in the agarose gel so that the wells are in the negative pole of 
the tank and the DNA can migrate toward the positive pole. 
- Allow to run the samples to a voltage between 40 and 120 V- Display the result 
of electrophoresis on a transilluminator UV and take a photo from gel. 
Methodologycal appendix  -130- 
 
6.10 Life cycle of Schistosoma mansoni in laboratory 
A strain of S. mansoni was maintained by laboratory passage in Biomphalaria glabrata 
snails and BALB/C strain mice (Cheever et al., 2002). Snails were kept in glass recipients 
with dechlorinated tap water and fed fresh lettuce ad libitum (Freire et al., 2002). Cercarial 
shedding was induced phototropically at 30 ºC and the parasites used for infection within 
three hours of emergence. Anaesthetized mice were infected with cercariae administered on 
a shaven abdomen and worms were subsequently perfused through an incised portal vein 
(Doenhoff et al., 1978). Count eggs in the liver and small intestine of infected mice 
according to Cheever et al., (2002) 
6.10.1 Infection of snails 
Materials 
- Livers of mice infected at 7 week of infection. 
- Homogenizator. 
- Sedimentation cup. 
- Saline solution: 8.5 g NaCl in a 1 l of destilled water. 
Technique: 
- Fragment and homogeneize the liver tissue in saline solution. 
- Add up to one liter of water and leave it for 20 min at 4ºC in darkness and remove foam 
and detritus. 
- Perform other more sedimentation as above. 
- Leave only 50 ml mineral water at the bottom of the sedimentation cup at 25-28ºC and 
light 
- Expose every snail with 7 miracidia 
- Mainain the snails at 24-28ºC during 4 weeks, then the snail put in light and 28ºC for 
cercariae hatching for 2 h. 
- Count three times for establish the average individual dosis 
6.10.2 Infection of mice 
Materials 
- Adhesive tape 
- Anestesia (Ketamin 100-200 mg/kg and diazepam 5 mg/kg with atropine 40 µg/kg). 
- Plastic ring. 
Technique: 
- Injecte 100 µl of the anesthesic mixture. 
- Place the ring on the shaved abdomen. 
- Administrate 150±10 cercariae in 1 ml maximum. 
- Leave the darkness mice for 45 minutes.  
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6.10.3 Perfusion of mice: 
Materials 
- Mice infected with 150 cercariae of S. mansoni. 
- Scissors, tweezers. 
- Syringe and needle (0.5 mm). 
- Heparin saline. 
- Pentobarbital sodium, solution. 
- Potassium hydroxide 5%. 
- McMaster chamber. 
Technique 
- Anesthetize with sodium pentobarbital. 
- Cut and remove skin of the abdomen and access to the abdominal cavity. 
- Open the chest and inject heparin salin in the left ventricle. 
- Cut the portal vein to 0.5 cm, collect and count the worms. 
- Remove the liver and weigh it and immerse it in 50 ml of potassium hydroxide, 
incubate18 h a 37ºC and then count eggs per gram in a McMaster chamber. 
6.11 Adult worm antigens from S. mansoni (AWASm). 
Adult worm antigens (AWASm) from S. mansoni were made in accordance with Dunne 
et al. (1997).  
Materials: 
- Adult worm of Schistosoma mansoni. 
- Liquid nitrogen. 
- Mortar and paste. 
- Proteases inhibitors [1mM N-Tosyl-1 phenylalanine chloromethyl ketone and 
phenylmethylsulphonyl fluoride (PMSF)]. 
- Sterile filter with 0.22 µm. 
Procedure: 
- Recovered S. mansoni from the portal perfusion. 
- Wash the worms to be free of erythrocytes and submerge them in liquid nitrogen 
immediately. 
- All the worms ground into a paste, and centrifuge them at 10.000g at 4ºC for 1h. 
- Add proteases inhibitors (1mM of N-tosyl-1 phenylalanine chloromethyl ketone, 1mM 
of phenylmethylsulphonyl fluoride PMSF). 
- Centrifuge the soluble material and filtered through a 0.22 µm sterile filter. 
- Determination of protein concentration by Micro BCATM Assay. 
- Store at-80ºC. 
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6.12 Cercarial antigen of Schistosoma mansoni (CSm). 
Cercarial antigen (CSm) from S. mansoni was used accordance with Dunne et al. (1997). 
Materials: 
- Cercariae of S. mansoni. 
- Liquid nitrogen. 
- Proteases inhibitors [1mM N-Tosyl-1 phenylalanine chloromethyl ketone and 
phenylmethylsulphonyl fluoride (PMSF)]. 
- Sterile filter with 0.22 µm 
Procedure: 
- Recovered and harvest the cercariae of S. mansoni from intermediate host (infected 
snail). 
- Submerge them in liquid nitrogen immediately. 
- Sonicate, and centrifuge them at 10,000 x g at 4 ºC for 1h. 
- Add proteases inhibitors (1mM of N-Tosyl-1 phenylalanine chloromethyl ketone, 1mM 
of PMSF). 
- Centrifuge the soluble material and filtered through a 0.22 µm sterile filter. 
- Determination of protein concentration by Micro BCATM Assay. 
- Store at -80 ºC. 
6.13 Life cycle of Strongyloides venezuelensis in laboratory  
The third stage infective larvae (L3) of S. venezuelensis were obtained from the strain 
that is maintained at the Laboratory of Parasitology, Faculty of Pharmacy University of 
Salamanca by serial passage in Wistar rats. This line comes from the Laboratory of 
Taxonomy and Biology of Invertebrates, Department of Parasitology (Federal University of 
Minas Gerais, Belo Horizonte, Brazil) and was yield by Professor Alan L. de Melo. 
The cycle was performed in accordance with the technique of Martins et al. (1999), 
where from feces of infected animals recovering eggs of S. venezuelensis, to allow the 
development of these larvae of first (L1), second (L2) and third stage (L3). Feces were 
mixed with an inert substrate composed of vermiculite. After incubation at 28ºC for at least 
72 h, the L3 collected by a Baermann technique (Rugail et al., 1954). This technique is 
based on thermo-hydrotropism parasitic characteristic of this phase (Figure 5.1.) Larvae 3 
were counted and confirmed that at least 80% of worm have mobility. Finally 3.000 L3 in 
0.5 ml saline solution or PBS sterile was injected subcutaneously to male rats of 60-120 g 
(Figures 5.1 and 5.2). 
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Materials: 
- L3 of S. venezuelensis. 
- Wistar rat (100-150g). 
- Vermiculite. (Termite, Asfaltex, Sant Cugat Del Valles, Spain) 
- PBS. 
- Polycarbonate cages. 
- Wire mesh. 
- Funnel-size according to need 
- Funnel stand 
- Clamp or spring clip 
- Cheesecloth or dental napkin 
- Thin stick or metal rod 
- Strainer 
- Microscope 
- Test tube 12 ml 
- Pasteur pipette 
- Small Petri dishes 
- Scissors 
- Disposable paper towels 
- Spoon or spatula 
- Rubber band or length of string 
- Jug or flask 
- Microscope slides and coverslips 
Procedure: 
- Place the infected animals in cages on the grid. Basically it was necessary to filter paper 
moistened to prevent desiccation of the feces. 
- Collect and mix the feces of 24 hours with 20 ml of distilled water and vermiculite in 
sufficient quantity to maintain saturation of moisture and good aeration and incubate 3-7 
days at 28 ºC with relative humidity above 80%. 
- To infect male Wistar rats subcutaneously (sc) with third stage larvae of 
S. venezuelensis. 
- Rats keep in polycarbonate cages that have wire mesh with opening of 0.5cm2 is placed 
2 centimeters from the bottom. 
- Place some vet papers on the bottom of the cage to keep the faeces moist. 
- Collect the faeces after 48-72 hours. 
- Mix and homogenize well faeces with vermiculites. 
- Incubate coprocultures 3-5 days at 28ºC and 90%humidity. 
- Place a double layer of cheesecloth or dental napkin on a disposable paper towel or 
equivalent on bench. 
- Using a spoon or spatula weigh or measure approximately 5-10 g of faecal material. 
Then place faecal material in the centre of the cheesecloth (1). 
- Form a pouch containing the faecal material by holding the four corners of the 
cheesecloth together and moulding the cloth around the faecal material (2, 3, and 4). 
- Using a rubber band or length of string close the cheesecloth pouch and then push the 
stick or short metal rod under the rubber band or string so that the pouch can be worms 
suspended (5, 6). 
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- Place the pouch containing the faecal material in the funnel and trim off the excess 
cheesecloth (7). 
- Fill the funnel with lukewarm water (42ºC) and make sure the faecal material is well 
covered (8, 9) and leave the apparatus to stand for 45 min. 
- Draw off a few millilitres of fluid from the stem of the funnel into a test tube, and then 
either leave to sediment for at least 30 minutes or the fluid can be drawn into a 
centrifuge tube and spun at 1000 rpm for 2 minutes. 
- Check sediment sample in a Petri dish for the presence of larvae and collect larvae (L3) 
of S. venezuelensis, count them and consider motility and morbidity. 
 
 
Figure 5.1: Biological cycle of S. venezuelensis in the laboratory. Obtention of 
feaces from rats infected (1). Coporcultures (2). Subcutaneous infection (3). 
Incubator at 28ºC and more than 85% or relative humidity..  










Figure 5.2 The Baermann technique is based on the active migration or 
movement of larvae. Baermann apparatus (1). Faeces are plased on 8 layer of 
gauze (2), to enveloped (3, 4), then placed in the Baermann apparatus (5) and 
finally water at 42-44ªC is poured. Faeces are moisted by the water, larvae 
moved into and we can collect them. 
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6.14 Decontamination of larvae and female adult of S. venezuelensis 
Third stage of larvae and female adult of S. venezuelensis decontaminate according to 
Martins et al. (2000). Larvae and parthenogenetic females of S. venezuelensis obtained from 
stool culture and necropsy didn’t have sufficient features to be cultivated because microbial 
flora of the environment in which they were obtained, could contaminate the culture media. 
For all this, because to remove these contaminating organisms larvae and females of 
S. venezuelensis processed with sodium hypochlorite, antibiotics and antifungal in sterile 
distilled water. 
Materials: 
- Third stage larvae of S. venezuelensis 
- Female adult of S. venezuelensis 
- PBS sterile 
- Sodium hypochlorite 0.25 % (212297, Panreac). 
- Sterile distilled water 
- Sodium benzylpenicillin 180 µg/ml 
- Ceftazidime 1.0 mg/ml 
Procedures: 
- Wash larvae and adults with sterile distilled water 
- Treated with sodium hypochlorite 0.25% for 10 min 
- Wash with sterile distilled water 
- Exposed larvae and adults to Sodium benzylpenicillin 180 µg/ml and Ceftazidime 1.0 
mg/ml for 30-60 min 
- Wash with sterile distilled water 
- Store at -80 
6.15 Necropsy of mice infected with Strongyloides venezuelensis. 
Necropsy was performed to obtain larvae from lungs or adults from the intestine 
(Vlaminck, 2010) 
Materials 
- Scissors, tweezers 
- Saline solution: 8.5 g NaCl in a 1 l of destilled water. 
- Sedimentation cup 
Technique: 
- Sacrifice mice with cervical dislocation 
- Remove skin from the abdominal region and open the intestinal cavity. 
- Remove the upper 2/3 of the small intestine, cut open it longitudinally, and incubate in 
PBS at 37ºC for 2 h. 
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- Remove the lungs, fragmente in PBS, and incubate for 2 h at 37ºC. 
- Quantificate under stereo microscopy worms that emerge from each organ. 
6.16 Obtanining different antigens from third stage of larvae (L3) and female 
parthenogenetic from S. venezuelensis. 
Preparation of PBS-soluble extract antigen (L3-PBS) and excretory secretory of L3 from 
S. venezuelensis were done as described Conway et al. (1994). We obtained a total of eight 
proteins and metabolic products extracts from L3 and parthenogenetic females of 
S. venezuelensis.  
6.16.1 Soluble antigen preparation from S. venezuelensis L3 (L3-PBS). 
The soluble antigen in phosphate buffer solution (PBS) of L3 larvae of S. venezuelensis 
was obtained after various processes including:  freezing / thawing, homogenization and 
application of ultrasonic. This procedure was performed in a solution containing protease 
inhibitors (Conway et al., 1994). 
Material: 
- PBS sterile 
- Third stage larvae of S. venezuelensis  
- Protease inhibitors: (5mM ethylendiaminetetraacetic acid (EDTA), 2mM 
phenylmethylsulphonyl fluoride (PMSF)), 1µM pepstatin, 4µM aproptinin and 10 µM 
chymostatin) 
- NaOH 0.15 M 
- Syringe filter (Millipore) with 0.2 µm pore size 
- Dulbecco-modified Eagle’s Medium (DMEM) 
- Ethylenediaminetetraacetic acid (EDTA) in distilled water 1M (E-9884, Sigma). 
- Phenilmethysulfonylfluoride (PMSF) 0.33 M in ethanol (P-7626, Sigma). 
- Chemostatina in water (C-7268, Sigma). 
- Aprotinin in 0.9% NaCl saline (A-6012, Sigma). 
- 1M pepstatin A in ethanol. (P4265. Sigma). 
- Phosphate buffer solution (PBS) 0.14 M NaCl, 2.7 nM KCl, KH2PO4 1.5 nm, 
Na2HPO4 6.5 nM. 
- Sodium hydroxide 0.01 M (621845, Panreac). 
- Hydrochloric acid 1 M (181021, Panreac). 
- Semi-permeable membranes of cellophane. 
- Kit BCA protein determination: Micro BCA Protein Assay Kit (23235 Pierce). 
- Glass Homogenizer. 
- Sonicator. 
- Centrifuge. 
- Chamber cold at 4 °C. 
- Shaker with thermostat. 
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Procedure: 
- Wash larvae with sterile distilled water 
- Decontamination of larvae (Martins method) 
- Resuspended L3 at a concentration of approximately 2×105/ml in PBS with 5mM EDTA, 
2mM PMSF and Aproptinin 100 IU / ml, Pepstatin A 1 µM and Chemostin 1 mM. 
- Homogenize the suspension in ice-water bath 30-60 minutes. 
- Subsequently sonicate the suspension 8 times for 20 seconds at 70 kHz. 
- Incubate 1hr at 4ºC 
- Centrifuged at 13,000 g for 30 minutes at 4 ºC. 
- Collect the supernatant and store at -80ºC. 
- Determine the protein concentration in the supernatant by Micro BCA TM Assay. 
- Check the bands in a polyacrylamide gel with sodium dodecyl sulfate (SDS-PAGE) to 
12.5% stained with Coomassie blue. 
6.16.2 Alkaline extraction of adult female antigen of S. venezuelensis (F-ALK) 
This extract is obtained by exposing adult female worm of S. venezuelensis in an isotonic 
solution alkalinized with sodium hydroxide according to Machado et al. (2003) and Faccioli 
et al. (2003). 
Material: 
- PBS sterile. 
- Female adult worm of S. venezuelensis. 
- Protease inhibitors: (5mM ethylendiaminetetraacetic acid (EDTA), 2mM 
phenylmethylsulphonyl fluoride (PMSF)), 1µM Pepstatin, 4µM Aproptinin and 10 µM 
chymostatin). 
- NaOH 0.15 M. 
- Syringe filter (Millipore) with 0.2 µm pore size. 
- Dulbecco’s modified Eagle’s medium (DMEM, D-0819 Sigma). 
- Ethylenediaminetetraacetic acid (EDTA) in distilled water 1M (E-9884, Sigma). 
- Phenilmethysulfonylfluoride (PMSF) 0.33 M in ethanol (P-7626, Sigma). 
- Chymostatin in water (C-7268, Sigma). 
- Aprotinin in 0.9% NaCl saline (A-6012, Sigma). 
- Pepstatin A in ethanol 1 M (P4265, Sigma). 
- Phosphate buffer solution (PBS) 0.14 M NaCl, 2.7 nM KCl, KH2PO4 1.5 nM, Na2HPO4 
6.5 nM. 
- Sodium hydroxide 0.01 M (621845, Panreac). 
- Hydrochloric acid 1 M (181021, Panreac). 
- Semi-permeable membranes of cellophane. 
- Kit BCA protein determination: Micro BCA Protein Assay Kit (23235 Pierce). 
- Glass Homogenizer 
- Sonicator 
- Centrifuge 
- Chamber cold at 4 °C 
- Shaker with thermostat 
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Procedure: 
- Wash adult female worm with sterile distilled water and decontaminate them 
subsequently. 
- Suspended 1.000 adult worms in 20 ml of PBS  
- Add EDTA 5mM, PMSF 2 mM and Aprotinin 100UI/ml, Pepstatin A 1 µm and 
Chymostatin 1mM. 
- Add 1 ml of NaOH 0.15M/20ml of suspension of parasite. 
- Agitation the suspension slowly at 4ºC 6 hours 
- Add 0.3M of HCL (PH 7) 
- Sonicate the suspension 8 times for 20 seconds at 70 kHz 
- Centrifuge at 13,000 g for 30min at 4ºC 
- Store supernatant at -80 
- Determination of protein concentration by Micro BCA TM Assay and Check the bands 
in a polyacrylamide gel with sodium dodecyl sulfate (SDS-PAGE) to 12.5% stained 
with Coomassie blue. 
6.16.3 Preparation of the excretory/secretory of L3 (L3-ES) antigen form 
S. venezuelensis 
Excretory secretory antigens of third stage larvae of S. venezuelensis are prepared 
according to Northern and Grove (1990) (L3-ES).L3 S. venezuelensis were kept in distilled 
water and incubated at 28 ºC with good condition to have sufficient lighting. Due to the low 
feeding activity of the L3, it is necessary to be cultivated for 5 to 10 days to collect the 
products of excretion/secretion of the parasite according to Brindley et al. (1988). 
Materials: 
- Larvae 3 S. venezuelensis decontaminated. 
- Culture flasks 100 ml. 
- Incubator  
Procedure: 
- Resuspended 1500 L3/ml in 20 ml of PBS with penicillin 100 IU/ml, streptomycin 
0.1 mg/ml, fluconazol 0.8 mg/ml, 5 mM EDTA, 2 mM PMSF and Aprotinin 100 IU/ml, 
Pepstatin A 1 µM and chymostatin 1 mM. 
- Place in the incubator at 28ºC and humidity of 80%. 
- Check daily that the larvae are moving. Count was conducted over one hundred mobile 
L3. If bacterial contamination is detected larvae must be discarding. 
- Maintain the cultures until the mobile L3 are 30%. 
-  Centrifuge the culture at 1000 g, 5 minutes, and the supernatant collected and 
lyophilized. 
- Weigh the lyophilized and then rehydrate it to obtain a concentration around 1µg/µl. 
- Determine the protein concentration and check on a SDS-PAGE gel 12.5% stained with 
Coomassie blue. Store at - 80°C. 
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6.16.4 Female excretory/secretory antigens preparation of S. venezuelensis. 
Parthenogenetic female of S. venezuelensis once decontaminated, can be maintained in 
the laboratory for about a week with cell culture media, adding glucose and carbon dioxide 
atmosphere according to Maruyama and Nawa (1997). 
Materials 
- Female parthenogenetic S. venezuelensis decontaminated. 
- Dulbecco’s modified Eagle’s medium (DMEM, D-0819 Sigma). 
- Glucose 50% in PBS. 
- Culture flasks 100 ml. 
- Incubator with 5% CO2 at 37°C. 
Procedure: 
- Resuspended 30 females/ml in 20 ml PBS with 1% glucose, penicillin 100 IU/ml, 
streptomycin 0.1 mg/ml, fluconazol 0.8 mg/ml, 5 mM EDTA, 2 mM PMSF and 
Aprotinin 100 IU / ml, Pepstatin A 1 µM and chymostatin 1 mM in cell culture flasks at 
37°C with 5% CO2 and 80% humidity. 
- Add sugar daily to maintain a minimum of 1%, check the mobility of 100 females and 
control contamination with bacteria and other micro organism by Gram’s method in the 
culture medium. 
- Remove the culture medium every 3 days until mobility reach below 70%. 
- Centrifuge the culture at 1.000 g for 5 minutes, recovering the supernatant and freeze it 
at -80°C and lyophilized. 
- Rehydrate the lyophilized protein to obtain an approximate concentration of 1 mg/ml of 
antigen. 
- Remove the supernatant and store at -20 ºC. 
- Determination of protein concentration by Micro BCATM Assay and check the bands in 
SDS-PAGE gel 12.5% stained with Coomassie blue. 
6.17 Mc Master egg counting for quantitation of nematode eggs 
Fecal worm egg examination methods are based on the principle of differential density. 
In other words, parasites eggs sink in water, but they will float in various chemical solutions 
that are more dense than water because the eggs are lighter than the fluid used as a flotation 
solution. 
Materials: 
- Compound microscope. 
- Scale. 
- Saturate sodium chloride solution mix water with salt and add more salt then heat the 
mixture in pan with stirring until boiling. Then let it to cool at room temperature. The 
solution will look cloudy and some material will precipitate and now it OK. Pour clear 
part of solution into a dispensing container of dome kind and store at room temperature. 
Do not refrigerate as additional solute will precipitate. 
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- 50 ml centrifuge tube with screw cap. 
- Pipet (1 ml syringe or eye dropper works well) 
- McMaster egg counting slide. 
- Paper towels. 
- A fresh fecal sample should be collected and kept refrigerated until tested. 
Procedures: 
- Weight out 2 g of feces into a 50 ml centrifuge tube and fill to 30 ml with salt solution. 
- Pour off approximately 25 ml of the salt solution into another small container keeping 
feces in the tube. 
- Let soak for a few minutes and mix (soft feces) or break up (fecal pellets) with tongue 
blade. 
- Add back about ½ of the salt solution and mix well, breaking up any remaining feces 
and homogenize feces as best as possible. 
- Add back the remaining salt solution and screw the cap back onto the tube. 
- Shake tube vigorously for about 1 minute to disrupt any remaining feces as much as 
possible. 
- Set tube aside for a few minutes to let bubbles dissipate. 
- Wet McMaster chamber with water and dry top and bottom on paper towels. 
- Rock tube several times to thoroughly mix solution without causing large air bubbles to 
form. 
- Pipet immediately (using 1 ml syringe or eye dropper) a sample of the suspension and 
fill both sides of counting chamber. Work quickly. If it takes more than a few seconds to 
load the first chamber, then mix fecal solution again and refill pipet before loading the 
second chamber. 
- Let stand for 1-2 minutes to allow eggs to float to top. 
- Count all eggs inside of grid areas (greater than ½ of egg inside grid) using low power 
(10x) objective. Focus on the top layer, which contains the very small air bubbles (small 
black circles, if numerous large air bubbles are visible, remove the fluid and refill) 
- Count only trichostrongyle/strongyle eggs (oval shaped, ~80-90 µm). Do not count 
strongyloides (oval, ~50 microns long), tapeworm eggs (triangular/D-shaped) or 
coccidia (various sizes). Notations are made as to the presence of other species, but only 
the trichostrongyle/strongyle eggs are counted. 
- Once filled, the chambers can sit for no longer than 60 minutes before counting without 
causing problems. Longer than this and drying/crystal formation begin. 
- Total egg count (both chambers) ×50=EPG (eggs per gram). 
6.18 Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a biochemical technique used mainly in immunology to detect the presence of 
an antibody or an antigen in a sample. The ELISA has been used as a diagnostic tool in 
medicine and veterinary as well as a quality control check in various industries. Detection of 
an experimental Schistosoma mansoni infection in CD1 mice serum the IgG total, IgG1 and 
IgG2a has done by ELISA technique  
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Materials: 
- Microtiter plates of 96-Well. 
- Eppendorf tubes. 
- Twelve-channel pipettor. 
- Adjustable pipettor of 1ml. 
- Humid chamber. 
- Wash battle or ELISA plate washer. 
- Polystyrene microtiter plates (Costar, Cambridge, MA, USA) 
- Peroxidase rabbit anti-mouse immunoglobulin G (Sigma). 
- Peroxidase monoclonal anti-mouse immunoglobulin G1 and G2a (Nordic immunology) 
- Plate reader. 
- TMB. 
- Carbonate buffer. 
- Wash buffer. 
- Blocking buffer. 
Procedures: 
- Coate plates with 100 µl of either S. mansoni AWA per well at a previously determined 
protein concentration of 5 µg/ml diluted in carbonate buffer pH 9.6. 
- Place serum at a dilution of 1:100 was added to the wells. 
- Incubate for 1 hour at 37ºC. 
- Wash three times with 200 µl of PBS-Tween 20 per well. 
- Add horseradish peroxidase rabbit anti-mouse IgG, IgG1 or IgG2a at a dilution of 
1:1.000. 
- Wash three times with 200 µl of PBS-Tween 20 per well. 
- Incubate for 1 hour at 37ºC, with substrate solution ortho-phenylene diamine plus H2O2  
- Stop the reaction at 10 minutes with 3 N of H2SO4. 
- Read absorbances at 492 nm  
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